A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER
Phase: PHASE3
Conditions: Pneumococcal Disease
Sponsor: Pfizer

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 1
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE 
SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL 
CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE–NAÏVE ADULTS 18 
YEARS OF AGE AND OLDER
Investigational Product Number:
PF-06482077
Investigational Product Name:
20-valent Pneumococcal Conjugate Vaccine 
(20vPnC)
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:
2018-004279-11
Protocol Number:
B7471007
Phase:
3
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 2
Document History
Document
Version Date
Summary of Changes 
Amendment 2
11 February 2019
Section 1.3: Added benefit-risk 
assessment (country specific-
amendment, required for Sweden by 
the Swedish Medical Products 
Agency [MPA]). 
European Clinical Trials Database 
(EudraCT) Number: Updated to 
2018-004279-11.
Amendment 1
25 September 2018
Added editorial changes throughout 
the document to improve clarity and
to correct typographic errors.
Protocol Summary: Revised to 
reflect the modifications made in the 
body of the protocol.
Schedule of Activities: Expanded 
the age range for Cohort 1 to include 
subjects 65 years of age and older; 
added flexibility to the clinical 
assessment wording.
 
 
 
 
Sections 2.1, 2.2, 2.5, and 2.6: 
Revised the age range in applicable 
objectives and applicable endpoints
to include adults 65 years of age and 
older.
Section 3: Added the potential for 
investigator sites in Europe, 
increased the number of study 
subjects, updated the age range in 
Cohort 1, added information 
regarding approximate target 
enrollment numbers for certain age 
groups, and added information 
regarding age stratification.
Section 4.1: Revised the Cohort 1 
age range to include subjects 65
years of age and older.  Revised the 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 3
inclusion criteria to reflect flexibility 
in the clinical assessment.
Sections 6.1 and 6.2: Revised the 
scope of clinical assessment, 
allowing for physical examination 
based on medical history.
Section 7.2: Revised the section to 
reflect clinical assessment wording.  
Removed Fahrenheit and adjusted 
the temperature ranges in Table 7 to 
close any gaps between the ranges.
 
 
Section 8. Added instruction for the 
investigator to contact the sponsor 
or designee for SAEs occurring 
within 30 days after vaccination.
Section 9: Revised the Data 
Analysis/Statistical Methods 
summary to reflect the modifications 
made in the body of the protocol.
Section 9.1.1: Updated the study 
size and power information for 
Cohort 1 with the updated study 
size  
.
Section 9.1.2: Clarified that the 
immunogenicity bridging analysis 
will be performed between each of 
Cohort 2 and Cohort 3 and the 
subset of subjects 60 through 64 
years of age in Cohort 1.
 
 
 
 
 
 
CCI
CCI
CCI
CCI
C
C
I
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 4
Original Protocol
13 July 2018
Not applicable (N/A)
This amendment incorporates all revisions to date, including amendments made at the 
request of country health authorities and institutional review boards (IRBs)/ethics committees 
(ECs).
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 5
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................10
APPENDICES .........................................................................................................................10
PROTOCOL SUMMARY.......................................................................................................11
SCHEDULE OF ACTIVITIES................................................................................................16
1. INTRODUCTION ...............................................................................................................20
1.1. Indication.................................................................................................................20
1.2. Background and Rationale ......................................................................................20
1.2.1. Pneumococcal Disease................................................................................20
1.2.2. Vaccines to Prevent Pneumococcal Disease...............................................21
1.2.2.1. Pneumococcal Polysaccharide Vaccines...................................21
1.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines .................21
1.2.2.3. Rationale for 20vPnC and Study B7471007 .............................23
1.3. Benefit-Risk Assessment.........................................................................................24
2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................25
2.1. Primary Safety Objective (All Cohorts)..................................................................25
2.1.1. Primary Safety Endpoints (All Cohorts).....................................................25
2.2. Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)......25
2.2.1. Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and 
Older)...............................................................................................................25
2.3. Secondary Objective – Cohort 2 (50 Through 59 Years of Age)............................25
2.3.1. Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)................26
2.4. Secondary Objective – Cohort 3 (18 Through 49 Years of Age)............................26
2.4.1. Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)................26
2.5. Secondary Objective – All Cohorts.........................................................................26
2.5.1. Secondary Endpoints – All Cohorts ...........................................................26
26
26
3. STUDY DESIGN.................................................................................................................27
3.1. Duration of Subject Participation............................................................................30
3.2. Duration of the Study ..............................................................................................30
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 6
3.3. Number of Subjects.................................................................................................30
4. SUBJECT ELIGIBILITY CRITERIA.................................................................................30
4.1. Inclusion Criteria.....................................................................................................30
4.2. Exclusion Criteria....................................................................................................31
4.3. Temporary Delay Criteria .......................................................................................32
4.3.1. Criteria for Temporarily Delaying Vaccine Administration ......................32
4.3.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw..............33
4.4. Lifestyle Requirements ...........................................................................................33
4.4.1. Contraception..............................................................................................33
4.5. Sponsor’s Qualified Medical Personnel..................................................................33
5. INVESTIGATIONAL PRODUCTS ...................................................................................33
5.1. Allocation to Investigational Product......................................................................34
5.2. Blinding of Site Personnel.......................................................................................34
5.3. Blinding of the Sponsor...........................................................................................34
5.4. Breaking the Blind ..................................................................................................35
5.5. Subject Compliance.................................................................................................35
5.6. Investigational Product Supplies.............................................................................35
5.6.1. Dosage Form(s) and Packaging..................................................................35
5.6.2. Preparation and Dispensing........................................................................36
5.7. Administration.........................................................................................................36
5.8. Investigational Product Storage ..............................................................................37
5.9. Investigational Product Accountability...................................................................38
5.9.1. Destruction of Investigational Product Supplies ........................................38
5.10. Concomitant Treatment(s).....................................................................................38
5.11. Prohibited Concomitant Treatments......................................................................38
5.12. Permitted Concomitant Treatments.......................................................................38
5.13. Recording Concomitant Treatments......................................................................39
6. STUDY PROCEDURES .....................................................................................................39
6.1. Cohort 1...................................................................................................................39
6.1.1. Cohort 1: Visit 1 (Vaccination 1 – Day 1)..................................................39
6.1.2. Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)................41
6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 7
6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] –
168 to 196 Days After Vaccination 1).............................................................42
6.2. Cohorts 2 and 3 .......................................................................................................43
6.2.1. Cohorts 2 and 3: Visit 1 (Vaccination – Day 1) .........................................43
6.2.2. Cohorts 2 and 3: Visit 2 (Follow-up – 28 to 42 Days After Visit 1)..........45
6.2.3. Cohorts 2 and 3: Visit 3 (6-Month Safety Collection [Telephone 
Contact] – 168 to 196 Days After Vaccination 1) ...........................................45
6.3. Unscheduled Visits (All Cohorts) ...........................................................................46
6.4. Subject Withdrawal.................................................................................................47
7. ASSESSMENTS..................................................................................................................48
7.1. Pregnancy Testing...................................................................................................48
7.2. Safety Parameters....................................................................................................49
7.2.1. Subject Electronic Diary.............................................................................49
7.2.2. Grading Scale for Prompted Events ...........................................................50
7.2.2.1. Local Reactions.........................................................................50
7.2.2.2. Systemic Events ........................................................................51
7.2.2.3. Fever..........................................................................................52
7.2.2.4. Use of Antipyretic/Pain Medication..........................................53
7.3. Immunogenicity ......................................................................................................53
7.4. Biological Samples..................................................................................................54
8. ADVERSE EVENT REPORTING......................................................................................54
8.1. Requirements...........................................................................................................54
8.1.1. Additional Details on Recording Adverse Events on the CRF...................55
8.1.2. Eliciting Adverse Event Information..........................................................55
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the 
Subject Withdrawal section)............................................................................56
8.1.4. Time Period for Collecting AE/SAE Information......................................56
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................56
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF...................57
8.1.5. Causality Assessment .................................................................................57
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................57
8.2. Definitions...............................................................................................................57
8.2.1. Adverse Events...........................................................................................57

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 8
8.2.2. Abnormal Test Findings .............................................................................58
8.2.3. Serious Adverse Events..............................................................................58
8.2.4. Hospitalization............................................................................................60
8.3. Severity Assessment................................................................................................61
8.4. Special Situations ....................................................................................................61
8.4.1. Protocol-Specified Serious Adverse Events...............................................61
8.4.2. Potential Cases of Drug-Induced Liver Injury............................................61
8.4.3. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure.....................................................63
8.4.3.1. Exposure During Pregnancy......................................................63
8.4.3.2. Exposure During Breastfeeding ................................................63
8.4.3.3. Occupational Exposure .............................................................63
8.4.4. Medication Errors and Lack of Efficacy ....................................................64
8.4.4.1. Medication Errors......................................................................64
8.4.4.2. Lack of Efficacy........................................................................65
8.5. Medical Device Complaint Reporting Requirements .............................................65
9. DATA ANALYSIS/STATISTICAL METHODS...............................................................65
9.1. Sample Size Determination and Hypothesis Testing ..............................................65
9.1.1. Cohort 1 (Subjects 60 Years of Age and Older).........................................65
9.1.2. Cohort 2 (Subjects 50 Through 59 Years of Age) and Cohort 3 
(Subjects 18 Through 49 Years of Age) Compared to Subjects 60 
Through 64 Years of Age From Cohort 1........................................................68
9.2. Analysis Populations...............................................................................................68
9.2.1. Safety Population........................................................................................68
9.2.2. Immunogenicity Population for Cohort 1...................................................69
9.2.3. Immunogenicity Population for Comparison of Cohorts 2 and 3 to 
Cohort 1 ...........................................................................................................70
70
9.2.5. Analysis of Demographic and Clinical Characteristics..............................70
9.3. Immunogenicity Analyses.......................................................................................70
9.3.1. Immunogenicity Analysis Comparing 20vPnC/Saline to 
13vPnC/PPSV23 in Cohort 1...........................................................................71
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 9
9.3.2. Immunogenicity Analysis Comparing Younger Cohorts (Subjects 50 
Through 59 Years of Age and Subjects 18 Through 49 Years of Age) to 
Subjects 60 Through 64 Years of Age From Cohort 1, Limited to 
Subjects Receiving 20vPnC (Bridging Analyses) ...........................................72
9.3.3. Other Immunogenicity Analyses for Cohorts 2 and 3 Based on OPA 
Titer of 20vPnC................................................................................................72
73
73
73
9.3.7. Other Immunogenicity Analyses ................................................................74
74
9.4. Safety Analysis........................................................................................................75
9.4.1. Adverse Events...........................................................................................75
9.4.2. Reactogenicity ............................................................................................75
.75
.76
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................76
11. DATA HANDLING AND RECORD KEEPING .............................................................77
11.1. Case Report Forms/Electronic Data Record .........................................................77
11.2. Record Retention...................................................................................................78
12. ETHICS..............................................................................................................................78
12.1. Institutional Review Board/Ethics Committee......................................................78
12.2. Ethical Conduct of the Study ................................................................................78
12.3. Subject Information and Consent..........................................................................78
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................79
13. DEFINITION OF END OF TRIAL...................................................................................80
13.1. End of Trial in All Participating Countries ...........................................................80
14. SPONSOR DISCONTINUATION CRITERIA ................................................................80
15. PUBLICATION OF STUDY RESULTS..........................................................................80
15.1. Communication of Results by Pfizer ....................................................................80
15.2. Publications by Investigators ................................................................................81
CCI
CCI
CCI
CCI
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 10
16. REFERENCES ..................................................................................................................83
LIST OF TABLES
Table 1.
Cohort 1 (60 Years of Age and Older): Schedule of Activities................16
Table 2.
Cohort 2 (50 Through 59 Years of Age) and Cohort 3 (18 Through 
49 Years of Age): Schedule of Activities.................................................18
Table 3.
Vaccinations Given to Each Cohort .........................................................27
Table 4.
Applicable Control Groups for Safety and Immunogenicity 
Assessments – Cohorts 1, 2, and 3 ...........................................................29
Table 5.
Grading Scales for Local Reactions .........................................................51
Table 6.
Grading Scales for Systemic Events.........................................................52
Table 7.
Ranges for Fever.......................................................................................52
67
APPENDICES
Appendix 1. Abbreviations......................................................................................................90
92
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 11
PROTOCOL SUMMARY
Background and Rationale
Streptococcus pneumoniae are gram-positive encapsulated cocci that have been a leading 
cause of bacteremia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and 
continue to be a major global public health concern.  Serious pneumococcal disease may 
occur at any age; however, children <5 years and adults 65 years of age are at particularly 
increased risk.  Individuals with certain comorbidities and immunocompromising conditions 
are also at risk.  S pneumoniae remains an important cause of serious disease in the United 
States and worldwide.  Globally, pneumococcal pneumonia was estimated to cause 
approximately 1,517,000 deaths in 2015 and, across all ages, accounted for approximately 
55% of deaths due to lower respiratory tract infections.
The polysaccharide capsule has been identified as an important virulence factor for this 
pathogen.  While more than 95 pneumococcal serotypes differentiated by their capsular 
polysaccharide composition have been identified, only a subset of serotypes are more 
commonly associated with severe disease.  Pneumococcal disease can be prevented with 
polysaccharide-based vaccines that induce antibody responses with functional 
(opsonophagocytic) activity and target the capsular serotypes responsible for disease.  
Pneumococcal vaccines that contain free polysaccharides, such as the licensed 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) formulated with capsular polysaccharides 
for 23 pneumococcal serotypes, elicit a T-cell–independent immune response.  These 
vaccines are poorly immunogenic for many of the serotypes contained in the vaccine in 
children less than 2 years of age, immunocompromised populations, and older adults.  They 
do not induce memory responses in any population, and have limited or no protection against 
nonbacteremic disease, including community-acquired pneumonia (CAP).  Pneumococcal 
conjugate vaccines, which contain capsular polysaccharides covalently linked to a protein 
carrier, elicit a T-cell–dependent immune response inducing protective responses in young 
children, older adults, and populations with high-risk conditions, as well as memory 
responses and protection against nonbacteremic disease.
Prevnar(7-valent pneumococcal conjugate vaccine), which was licensed in the United 
States in 2000, and Prevnar 13(13-valent pneumococcal conjugate vaccine [13vPnC]), 
which was licensed in the United States in 2010, are pneumococcal conjugate vaccines 
containing 7 and 13 capsular polysaccharides, respectively.  The pneumococcal capsular 
polysaccharides in those vaccines are individually conjugated to cross-reactive material 197 
(CRM197), a nontoxic variant of diphtheria toxin.  These vaccines target serotypes that caused 
the majority of pneumococcal disease in infants and older adults at the time of their 
introduction.  They have demonstrated efficacy/effectiveness against vaccine-type (VT) 
invasive pneumococcal disease (IPD), AOM, and pneumonia and the ability to reduce 
nasopharyngeal carriage and transmission, resulting in indirect beneficial effects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 12
Pfizer is developing a new 20-valent pneumococcal conjugate vaccine (20vPnC) candidate to 
further expand protection against the global burden of vaccine-preventable pneumococcal 
disease in children and adults over that of Prevnar 13.  20vPnC has the same composition as 
Prevnar 13, but contains an additional 7 pneumococcal conjugates to protect against 
serotypes responsible for a substantial burden of remaining pneumococcal disease.  20vPnC 
uses the same platform as Prevnar and Prevnar 13 and contains components that have 
undergone extensive clinical research.  Safety and immunogenicity data from a 20vPnC 
Phase 1 study conducted in healthy adults 18 through 49 years of age and from a Phase 2 
study in adults 60 through 64 years of age demonstrate the vaccine induces immune 
responses to the 20 vaccine serotypes and has a safety profile consistent with other 
pneumococcal conjugate vaccines.  These data support clinical development in adult and 
pediatric populations.  See the 20vPnC investigator’s brochure for additional details.
 
 The Phase 3 study described in this 
protocol will provide safety data in adults ≥18 years of age and provide key immunogenicity 
data in each of 3 specific age groups (18 through 49, 50 through 59, and ≥60 years of age).
Study Design
This Phase 3, multicenter, randomized, double-blind study will be conducted at investigator 
sites in the United States and Europe.  Approximately 3880 adults 18 years of age and older 
with no history of pneumococcal vaccination will be enrolled into 1 of 3 cohorts based on 
their age at enrollment, and randomized to 1 of 2 vaccine groups (20vPnC or control).
Cohort 1: Approximately 3000 subjects 60 years of age and older at enrollment will be 
assigned to Cohort 1 and will be randomized (1:1) into 1 of 2 vaccine groups.  Each subject 
will receive either 20vPnC or 13vPnC (control vaccine) at Vaccination 1.  Subjects in 
Cohort 1 who received 20vPnC at Vaccination 1 will receive saline at Vaccination 2.  
Subjects in Cohort 1 who received 13vPnC at Vaccination 1 will receive PPSV23 at 
Vaccination 2.  Approximately 2000 subjects 60 through 64 years of age and 1000 subjects 
65 years of age and older will be enrolled and stratified by age.
Cohort 2: Approximately 440 subjects 50 through 59 years of age at enrollment will be 
assigned to Cohort 2 and randomized (3:1) into 1 of 2 vaccine groups to receive 20vPnC or 
13vPnC at Visit 1.
Cohort 3: Approximately 440 subjects 18 through 49 years of age at enrollment will be 
assigned to Cohort 3 and randomized (3:1) into 1 of 2 vaccine groups to receive either 
20vPnC or 13vPnC at Visit 1.
On Day 1 (Visit 1), subjects will be assessed for eligibility, have blood drawn for 
immunogenicity assessments, and receive 20vPnC or 13vPnC.  Subjects will be observed for 
at least 30 minutes after vaccination by blinded site staff, who will record adverse events 
(AEs) occurring during that time.  Subjects will also receive safety follow-up and electronic 
diary (e-diary) instructions at the visit.  Prompted systemic events (fever, headache, fatigue, 
muscle pain, and joint pain) occurring within 7 days after vaccination and prompted local 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 13
reactions (redness, swelling, and pain at the injection site) occurring at the 20vPnC or 
13vPnC injection site within 10 days after vaccination will be collected daily in the e-diary.  
Use of antipyretic/pain medications will be collected daily in an e-diary for 7 days after 
vaccination.
Subjects in Cohort 1 will return for Visit 2 (28 to 42 days after Visit 1), and information 
will be collected from the subjects on AEs, serious adverse events (SAEs), newly diagnosed 
chronic medical conditions (NDCMCs), and e-diary follow-up (as needed).  Blood will be 
drawn for immunogenicity assessments.  Saline will be administered to subjects who 
previously received 20vPnC, and PPSV23 will be administered to subjects who previously 
received 13vPnC, by a third-party unblinded site staff member.  Subjects will be observed for 
at least 30 minutes after vaccination by blinded site staff, who will record AEs occurring 
during that time.  Subjects will also be reminded about safety follow-up.
The subjects in Cohort 1 will return for Visit 3 (28 to 42 days after Visit 2) and information 
will be collected from the subjects on AEs, SAEs, and NDCMCs.  Blood will be drawn for 
immunogenicity assessments.
Subjects in Cohorts 2 and 3 will return for Visit 2 (28 to 42 days after Visit 1), and 
information will be collected from the subjects on AEs, SAEs, NDCMCs and e-diary 
follow-up (as needed).  Blood will be drawn for immunogenicity assessments.
Cohorts 1, 2, and 3 will have a final visit, approximately 6 months [168 to 196 days] after 
Visit 1; for this visit, the sites will contact the subject in all cohorts via telephone to inquire 
about SAEs, NDCMCs, and nonstudy vaccinations, as well as concomitant medications used 
to treat SAEs or NDCMCs.
 
 
 
Objectives and Endpoints
Primary Safety Objective (All Cohorts)
•
To describe the safety profile of 20vPnC in adults 18 years of age and older.
Primary Safety Endpoints (All Cohorts)
•
Reported prompted local reactions (redness, swelling, and pain at the injection site)
within 10 days after vaccination.
•
Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint 
pain) within 7 days after vaccination.
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 14

Reported AEs within 1 month after vaccination.

Reported SAEs and NDCMCs within 6 months after vaccination.
Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)

To demonstrate that the immune responses to the 13 serotypes in 13vPnC (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by 20vPnC in adults 60 years of age 
and older are noninferior to the immune response induced by 13vPnC.

To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 
12F, 15B, 22F, and 33F) induced by 20vPnC in adults 60 years of age and older are 
noninferior to the immune response induced by PPSV23.
Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and Older)

Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination.
Secondary Objective – Cohort 2 (50 Through 59 Years of Age)

To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in 
adults 50 through 59 years of age are noninferior to the immune responses induced by 
20vPnC in adults 60 through 64 years of age.
Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)

Serotype-specific OPA titers 1 month after vaccination.
Secondary Objective – Cohort 3 (18 Through 49 Years of Age)

To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in 
adults 18 through 49 years of age are noninferior to the immune responses induced by 
20vPnC in adults 60 through 64 years of age.
Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)

Serotype-specific OPA titers 1 month after vaccination.
Secondary Objective – All Cohorts

To describe the immune responses to 20vPnC in adults 60 years of age and older, 
50 through 59 years of age, and 18 through 49 years of age.
Secondary Endpoints – All Cohorts

Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 15
•
4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
•
Serotype-specific OPA titers greater than or equal to the lower limit of quantitation 
(≥LLOQ) 1 month after vaccination.
 
 
 
 
 
 
 
Statistical Methods
Primary immunogenicity objectives will be evaluated by formal hypothesis tests for 
noninferiority between the 20vPnC/saline and 13vPnC/PPSV23 vaccine groups in Cohort 1. 
Noninferiority for a serotype will be declared if the lower bound of the 2-sided confidence 
interval for the serotype-specific OPA geometric mean ratio (GMR) of 20vPnC relative to 
control is greater than 0.5 (2-fold criterion).
 
 
 Serotype-specific OPA geometric means, serotype-specific OPA geometric mean 
fold rises, percentages of subject with OPA titers ≥LLOQ, and ≥4-fold rises in OPA titers, 
 
will also be 
provided for each vaccine group and each cohort.
The safety objectives will be evaluated by summary statistics for local reactions, systemic 
events, and AEs, including SAEs and NDCMCs for each vaccine group and each cohort.
CCI
CCI
C
CI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 16
SCHEDULE OF ACTIVITIES
The Schedule of Activities table provides an overview of the protocol visits and procedures.  Refer to the Study Procedures and 
Assessments sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol.
The investigator may schedule visits (unplanned visits) in addition to those listed on the Schedule of Activities table, in order to 
conduct evaluations or assessments required to protect the well-being of the subject.
Table 1.
Cohort 1 (60 Years of Age and Older): Schedule of Activities
Visit Number
1
2
3
4
Visit Description
Vaccination 1
Vaccination 2
Follow-up After 
Vaccination 2
6-Month Safety 
Collection
Visit Type
Clinic Visit
Clinic Visit
Clinic Visit
Telephone Contact
Visit Window (Days)
Day 1
28 to 42 Days 
After 
Vaccination 1
28 to 42 Days 
After 
Vaccination 2
168 to 196 Days 
After Vaccination 1
Obtain informed consent
X
Assign subject number
X
Record demography 
X
Conduct clinical assessment, including collecting medical history data and 
smoking history
X
Record medications currently being taken for medical conditions
X
Record nonstudy vaccinations and concomitant medicationsa
X
X
X
X
Measure height and weight 
X
Measure prevaccination oral temperature
X
X
Contraception check, if applicableb
X
X
X
Review inclusion and exclusion criteria
X
Review temporary delay criteria
X
X
X
Review continued eligibility
X
X
Assign randomization number
X
Obtain blood sample for immunogenicity (~50 mL)c
X
X
X
Administer investigational product
X
X
Assess and record acute (immediate) reactions for at least 30 minutes after 
investigational product administration
X
X

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 17
Table 1.
Cohort 1 (60 Years of Age and Older): Schedule of Activities
Visit Number
1
2
3
4
Visit Description
Vaccination 1
Vaccination 2
Follow-up After 
Vaccination 2
6-Month Safety 
Collection
Visit Type
Clinic Visit
Clinic Visit
Clinic Visit
Telephone Contact
Visit Window (Days)
Day 1
28 to 42 Days 
After 
Vaccination 1
28 to 42 Days 
After 
Vaccination 2
168 to 196 Days 
After Vaccination 1
Provide subject with an e-diary, thermometer, and measuring device and instruct 
how to collect prompted local reactions, systemic events, and use of 
pain/antipyretic medicationsd
X
Review e-diarye
X
Collect e-diary 
X
Record and report adverse events
X---------------------------------------------------X
Record and report serious adverse events and newly diagnosed chronic medical 
conditionsf
X--------------------------------------------------------------------------X
Abbreviation: e-diary = electronic diary, 
a.
Record nonstudy vaccinations as well as concomitant medications used to treat SAEs or newly diagnosed chronic medical conditions.
b.
The investigator or designee will inform male subjects who are able to father children of the need to use highly effective contraception consistently and 
correctly until 28 days after the last dose of investigational product and document the conversation and the subject’s affirmation in the subject’s chart.
c.
Blood sample will be collected prior to vaccination.
d.
Subjects will record in an e-diary prompted local reactions and systemic events occurring within 10 and 7 days, respectively, after Vaccination 1. Use of 
antipyretic/pain medications will also be prompted for and collected daily in an e-diary for 7 days after Vaccination 1.  Subjects will be instructed to contact 
the study staff if they experience redness or swelling measuring >20 measuring device units or severe pain at the injection site or any Grade 4 prompted 
systemic event.
e.
Designated site staff will review e-diary data online at frequent intervals for the 10 days following Vaccination 1 to evaluate subject compliance and reported 
events as part of the ongoing safety review and will collect the e-diary at Visit 2.
f.
A newly diagnosed chronic medical condition is defined as a disease or medical condition, not previously identified, that is expected to be persistent or 
otherwise long-lasting in its effects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 18
Table 2.
Cohort 2 (50 Through 59 Years of Age) and Cohort 3 (18 Through 49 Years of Age): Schedule of Activities
Visit Number
1
2
3
Visit Description
Vaccination 1
Follow-up After 
Vaccination 1
6-Month Safety Collection
Visit Type
Clinic Visit
Clinic Visit
Telephone Contact
Visit Window (Days)
Day 1
28 to 42 Days
After Vaccination 1
168 to 196 Days After 
Vaccination 1
Obtain informed consent
X
Assign subject number
X
Record demography 
X
Conduct clinical assessment, including collecting medical history data and 
smoking history
X
Record medications currently being taken for medical conditions
X
Record nonstudy vaccinations and concomitant medicationsa
X
X
X
Measure height and weight 
X
Measure prevaccination oral temperature
X
Contraception check, if applicableb
X
X
Perform urine pregnancy test for female subjects of childbearing potential 
X
Review inclusion and exclusion criteria
X
Review temporary delay criteria
X
X
Review continued eligibility
X
Assign randomization number
X
Obtain blood sample for immunogenicity (~50 mL)c
X
X
Administer investigational product
X
Assess and record acute (immediate) reactions for at least 30 minutes after 
investigational product administration
X
Provide subject with an e-diary, thermometer, and measuring device and instruct 
how to collect prompted local reactions, systemic events, and use of 
pain/antipyretic medicationsd
X
Review e-diarye
X
Collect e-diary 
X

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 19
Table 2.
Cohort 2 (50 Through 59 Years of Age) and Cohort 3 (18 Through 49 Years of Age): Schedule of Activities
Visit Number
1
2
3
Visit Description
Vaccination 1
Follow-up After 
Vaccination 1
6-Month Safety Collection
Visit Type
Clinic Visit
Clinic Visit
Telephone Contact
Visit Window (Days)
Day 1
28 to 42 Days
After Vaccination 1
168 to 196 Days After 
Vaccination 1
Record and report adverse events
X---------------------------------X
Record and report serious adverse events and newly diagnosed chronic medical 
conditionsf
X-----------------------------------------------------------------------X
Abbreviation: e-diary = electronic diary.
a.
Record nonstudy vaccinations as well as concomitant medications used to treat SAEs or newly diagnosed chronic medical conditions.
b.
The investigator or designee will inform female subjects of childbearing potential and male subjects who are able to father children of the need to use highly 
effective contraception consistently and correctly until 28 days after the last dose of investigational product and document the conversation and the subject’s 
affirmation in the subject’s chart.
c.
Blood sample will be collected prior to vaccination.
d.
Subjects will record in an e-diary prompted local reactions and systemic events occurring within 10 and 7 days, respectively, after Vaccination 1. Use of 
antipyretic/pain medications will also be prompted for and collected daily in an e-diary for 7 days after Vaccination 1.  Subjects will be instructed to contact 
the study staff if they experience redness or swelling measuring >20 measuring device units or severe pain at the injection site or any Grade 4 prompted 
systemic event.
e.
Designated site staff will review e-diary data online at frequent intervals for the 10 days following Vaccination 1 to evaluate subject compliance and reported 
events as part of the ongoing safety review and will collect the e-diary at Visit 2.
f.
A newly diagnosed chronic medical condition is defined as a disease or medical condition, not previously identified, that is expected to be persistent or 
otherwise long-lasting in its effects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 20
1. INTRODUCTION
1.1. Indication
20-valent pneumococcal conjugate vaccine (20vPnC) is being developed for:

Active immunization to prevent disease caused by the Streptococcus pneumoniae
serotypes in the vaccine.
1.2. Background and Rationale
1.2.1. Pneumococcal Disease
S pneumoniae are gram-positive encapsulated cocci that have been a leading cause of 
bacteremia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and continue to 
be a major global public health concern.1,2,3 Serious pneumococcal disease may occur at any 
age; however, children <5 years and adults 65 years of age are at particularly increased 
risk.4 Individuals with certain comorbidities and immunocompromising conditions are also 
at increased risk.  Surveillance studies conducted in 2010-2012 by the Centers for Disease 
Control and Prevention (CDC) found that S pneumoniae remains among the most common 
bacterial pathogens identified in community-acquired pneumonia (CAP) requiring 
hospitalization in the United States in both children and adults.5,6  Bacteremic pneumococcal 
pneumonia (accounting for the majority of invasive pneumococcal disease [IPD] in adults) is 
less common than nonbacteremic pneumococcal pneumonia (an estimated 3 or more cases of 
nonbacteremic pneumococcal pneumonia occur for every 1 case of bacteremic pneumonia).  
Both bacteremic and nonbacteremic pneumococcal pneumonia are associated with significant 
morbidity and mortality in all age groups.1  Pneumococcal disease in older adults represents a 
high clinical and economic healthcare burden.  In Australia the incidence of hospitalization 
for all-cause pneumonia in adults ≥65 years of age, from 2011 through 2012, corresponded to 
an incidence rate of 1347/100,000 population.  Incidence rates were higher in adults 
≥85 years of age (3507/100,000).  Pneumococcal pneumonia accounted for 20.6% of 
pneumonia hospitalizations, with an incidence of 274/100,000 population.7  In a study of the 
global burden of disease using data from 195 countries, it was estimated that in 2015 lower 
respiratory tract infections (LRIs) were the leading infectious cause of death and the fifth 
leading cause of death overall, causing 2.74 million deaths globally.  Pneumococcal 
pneumonia caused 55.4% of LRI deaths in all ages, totaling 1,517,388 deaths; of those,
approximately 400,000 deaths were in children younger than 5 years and approximately 
700,000 deaths were in adults ≥70 years of age.8  The CDC estimated that in 2016 there were 
30,400 cases and 3690 deaths due to IPD in the United States.9  As these numbers suggest, 
S pneumoniae remains an important cause of serious disease in the United States and 
worldwide.
The polysaccharide capsule has been identified as an important virulence factor for this 
pathogen.  While more than 95 pneumococcal serotypes differentiated by their capsular 
polysaccharide composition have been identified, only a subset of serotypes are more 
commonly associated with severe disease.10,11  Anticapsular antibodies directed against the 
specific serotype bind to the capsule and promote complement-mediated opsonophagocytic 
killing and clearance of the organism.12

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 21
Pneumococcal disease can be prevented with polysaccharide-based vaccines that induce 
antibody responses with functional (opsonophagocytic) activity and target the capsular 
serotypes responsible for disease.13
1.2.2. Vaccines to Prevent Pneumococcal Disease
1.2.2.1. Pneumococcal Polysaccharide Vaccines
Vaccines containing free polysaccharides have been licensed since the 1970s.  One such 
vaccine, the 23-valent pneumococcal polysaccharide vaccine (PPSV23), has been licensed in 
the United States since 1983.14,15 PPSV23 contains capsular polysaccharides for 23 
serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F, and 33F).  PPSV23 elicits a T-cell–independent immune response.  Unconjugated 
polysaccharide vaccines do not induce robust responses in certain populations 
(eg, immunocompromised persons, children <2 years of age, and adults ≥65 years of age), 
nor do they generate immunologic memory, so their protective effect wanes over 2 to 
5 years.4,15,16,17  Moreover, their ability to prevent nonbacteremic pneumonia and AOM is 
limited or lacking.13,17,18,19  They also do not have an impact on nasopharyngeal carriage, and 
therefore do not afford herd protection.20 Another limitation is that in several studies,
individuals vaccinated with pneumococcal polysaccharide vaccine had lower functional
antibody responses following subsequent vaccination with either another dose of
pneumococcal polysaccharide vaccine or a dose of pneumococcal conjugate vaccine,
compared to the first dose of polysaccharide vaccine.21,22,23  Such ͆hyporesponsiveness͇
has been observed with other polysaccharide vaccines as well, and raises concern regarding 
the quality of response after revaccination or natural exposure to an invading vaccine-type 
(VT) pneumococcus.24  Despite waning immunity, these concerns of hyporesponsiveness, as 
well as other factors, have led most recommending bodies to restrict PPSV23 to a single 
lifetime dose in adults ≥65 years of age and 1 to 2 doses in most other high-risk
populations.24,25,26
1.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines
Pneumococcal conjugate vaccines contain polysaccharides that are covalently linked 
(conjugated) to an immunogenic protein.  This modification results in T-cell–dependent 
immune responses, which have been shown to be protective in young children, older adults, 
and populations with high-risk conditions and also induce memory responses.16,27 Prevnar®
(7-valent pneumococcal conjugate vaccine [7vPnC]) was the first pneumococcal conjugate 
vaccine to be licensed (in the United States in 2000) and was indicated for prevention of 
pneumococcal disease in infants and young children.  7vPnC contained 7 pneumococcal 
capsular polysaccharides each conjugated to cross-reactive material 197 (CRM197), a 
nontoxic variant of diphtheria toxin.  The pneumococcal capsular polysaccharide conjugates 
represented the serogroups/serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) responsible for most 
of the IPD and AOM in young children in the United States (80%-90% of IPD) and much of 
the world at the time (1998 to 2000).28,29,30,31,32 These serotypes also accounted for a high 
proportion of antibiotic-resistant strains.33 7vPnC demonstrated efficacy against VT IPD, 
pneumonia, and AOM in large randomized controlled efficacy studies in infants.34,35

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 22
The 7vPnC components contained in a related pneumococcal conjugate vaccine also were 
demonstrated to be efficacious against clinically/radiographically defined pneumonia.36,37
Following introduction of 7vPnC, reduction of nasopharyngeal carriage and transmission has 
resulted in indirect herd effects, with a 92% reduction of VT IPD in older adults 65 years of 
age.38,39
Prevnar 13(13-valent pneumococcal conjugate vaccine [13vPnC]) was developed to 
expand serotype coverage and was licensed in the United States in 2010.  13vPnC includes 
the same S pneumoniae serotypes as 7vPnC and an additional 6 polysaccharide conjugates 
for serotypes 1, 3, 5, 6A, 7F, and 19A.27,31,40  The vaccine was licensed for use in infants and 
young children based on comparisons of serotype-specific immunoglobulin G (IgG) to 
7vPnC, with supportive data to demonstrate the functional activity of the immune responses.  
13vPnC was subsequently licensed in adults based on an accelerated approval pathway 
demonstrating comparable serotype-specific opsonophagocytic activity (OPA) responses to 
PPSV23, followed by traditional approval based on demonstration of efficacy against VT 
CAP in CAPiTA (Community-Acquired Pneumonia Immunization Trial in Adults), a 
randomized controlled study of adults 65 years of age and older.41 Prevention of 
nonbacteremic VT CAP in this older adult population was also demonstrated and protection 
was observed through 4 years of follow-up.  This is notable given the lack of definitive data 
showing that PPSV23 prevents nonbacteremic disease in older adults, and evidence that 
protection against IPD wanes significantly over time.15  13vPnC has replaced 7vPnC and is 
licensed in the United States and many other countries, with national recommendations for 
use in children and older adults.42,43,44,45  It has also been prequalified by the World Health 
Organization (WHO) for use in national infant immunization programs in lower- and 
middle-income countries.46,47  Surveillance data from several countries following 
introduction of 13vPnC into the routine infant immunization program have demonstrated 
vaccine effectiveness against VT IPD in the vaccinated population.48,49,50
Prevnar 13 was licensed for adults 50 years of age in 2011, and recommended by the
Advisory Committee on Immunization Practices (ACIP) for use in adults with 
immunocompromising conditions in 2012. In July 2016, it was also licensed for use in adults 
18 through 49 years of age. The potential burden of VT CAP in adults in the United States 
was demonstrated by a study conducted well after the introduction of Prevnar into the routine 
infant immunization schedule, suggesting potential value in direct immunization of adults 
rather than reliance solely on the herd effect.51 The data on disease burden, combined with 
the results of CAPiTA, led to the August 2014 ACIP recommendation for all adults 
65 years of age to receive Prevnar 13, followed by PPSV23.26,52 The recommendation for 
Prevnar 13 was made based on the potential added benefit in protecting against disease, 
particularly nonbacteremic pneumonia caused by the vaccine serotypes. The continued 
recommendation for PPSV23 was intended to provide expanded protection against IPD for 
serotypes not in Prevnar 13. However, the prevalence of IPD due to most of the serotypes 
contained only in PPSV23 has remained stable or slightly increased in the United States and 
other countries despite continued recommendation and use of PPSV23 in adults 65 years of 
age and high-risk adults.53,54,55  These serotypes account for a significant amount of 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 23
pneumococcal disease, and their continued presence highlights the need for a better vaccine 
than PPSV23 to expand protection.
1.2.2.3. Rationale for 20vPnC and Study B7471007
20vPnC is being developed to further expand protection against the global burden of 
vaccine-preventable pneumococcal disease in children and adults over that of 13vPnC.  
20vPnC contains the serotypes present in 13vPnC plus 7 new serotypes (8, 10A, 11A, 12F, 
15B, 22F, and 33F).  The 7 additional serotypes were selected based on their relative 
prevalence as a cause of IPD, their generalized geographic distribution, and other factors that 
would support inclusion, such as the presence of antibiotic resistance and greater disease 
severity (eg, meningitis, mortality).56,57,58,59,60,61,62,63,64,65,66,67,68,69  These 7 serotypes are also 
present in PPSV23.70 Adding these 7 additional serotypes to the 13 serotypes in 13vPnC is 
anticipated to further reduce the global burden of pneumococcal disease and provide 
protection comparable to, or greater than, that of PPSV23.
The 20vPnC candidate is modeled after 7vPnC and 13vPnC, and contains polysaccharides of 
capsular serotypes of S pneumoniae, each covalently linked to CRM197.  
 
 
 
 
 
 
 
Safety and immunogenicity data from a Phase 1 study (B7471001) conducted in healthy 
adults 18 through 49 years of age and from a Phase 2 study (B7471002) in adults 60 through
64 years of age demonstrate that the vaccine induces immune responses to the 20 vaccine 
serotypes and has a safety profile consistent with other pneumococcal conjugate vaccines.  
These data support clinical development in adult and pediatric populations. See the 20vPnC 
IB for additional details.
 
This study is part of the clinical 
development program and the purpose of this study is to assess the safety and generate 
key immunogenicity data with 20vPnC in adults.
The pivotal immunogenicity comparison will be performed in the cohort of subjects 60 years 
of age and older. These subjects will receive 20vPnC and saline or 13vPnC and PPSV23 
separated by a 1-month interval. This follows the Phase 2 study design (B7471002) in 
subjects 60 through 64 years of age and facilitates comparison of responses to all serotypes in 
20vPnC to responses in licensed vaccines (13vPnC for the matched 13 serotypes, and 
PPSV23 for the 7 additional serotypes). Additionally, immune responses to 20vPnC in the 
younger age cohorts (18 through 49 years and 50 through 59 years) will be compared to 
20vPnC responses in the subset of subjects 60 through 64 years of age in the older cohort.
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 24
 
 
Additional information for this compound may be found in the summary of product 
characteristics (for 13vPnC and PPSV23) and the single reference safety document (SRSD). 
The SRSD for 20vPnC is the IB. The SRSD for 13vPnC is the US package insert (USPI). 
The SRSD for PPSV23 is the USPI.
1.3. Benefit-Risk Assessment
20vPnC has been administered to 33 adults 18 through 49 years of age in the Phase 1 Study 
B7471001 and to 221 adults 60 through 64 years of age in the Phase 2 Study B7471002.  The 
vaccine was well tolerated and the adverse event (AE) profile reflected events that may be 
observed in subjects in these age groups.  The most common AEs after 20vPnC 
administration were primarily related to local reactions (pain, redness, swelling) and systemic 
events (fever, fatigue, headache, muscle pain, joint pain).  20vPnC has not been evaluated in 
adults older than 65 years of age prior to this study.  
Both 13vPnC and PPSV23 are licensed vaccines, and the most common AEs noted after 
vaccination are primarily related to local reactions and systemic events.  Injection with saline 
(placebo) may produce pain and redness at the injection site.
As with any vaccine, an allergic reaction can occur. The allergic reaction can vary from skin 
rash to swelling of the face or lips and/or shortness of breath.  A severe allergic reaction 
(anaphylactic shock) may also occur. There may also be additional risks related to the 
vaccines administered in the study that are unknown at this time.
Risks that may be associated with study procedures include risk from blood sampling, such 
as feeling faint, fainting, pain, swelling, bruising, and infection where blood is taken.
Safety assessments described in the protocol and reviews of safety data by the investigator, 
sponsor study team  
 
 to monitor and mitigate these risks.
In the B7471001 and B7471002 studies, 20vPnC induced antibodies with functional 
(opsonophagocytic) activity to the pneumococcal serotypes in the vaccine; these antibodies 
may provide clinical benefit.  If 20vPnC is successful in Phase 3 studies and approved, it is 
anticipated to provide a public health benefit by reducing the burden of pneumococcal 
disease (invasive and noninvasive) due to vaccine serotypes.
13vPnC and PPSV23 are vaccines approved for the prevention of pneumococcal disease due 
to the serotypes in the vaccines, and may provide a clinical benefit to those receiving them.
CCI
CCI
CCI
CCI
C
C
I

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 25
Pfizer considers that the available information from Studies B7471001 and B7471002 with 
20vPnC, the available safety profile of similar pneumococcal conjugate vaccines 
(ie, 13vPnC), and the limited risks from study procedures support a favorable benefit-risk 
profile for 20vPnC and this study.
The current IB provides additional details on the B7471001 and B7471002 studies and the 
potential risks and benefits of 20vPnC.  Please refer to the respective summary of product 
characteristics/USPI for potential risks of licensed vaccines 13vPnC and PPSV23.
2. STUDY OBJECTIVES AND ENDPOINTS
2.1. Primary Safety Objective (All Cohorts)

To describe the safety profile of 20vPnC in adults 18 years of age and older.
2.1.1. Primary Safety Endpoints (All Cohorts)

Reported prompted local reactions (redness, swelling, and pain at the injection site)
within 10 days after vaccination.

Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint 
pain) within 7 days after vaccination.

Reported adverse events (AEs) within 1 month after vaccination.

Reported serious adverse events (SAEs) and newly diagnosed chronic medical 
conditions (NDCMCs) within 6 months after vaccination.
2.2. Primary Immunogenicity Objectives – Cohort 1 (60 Years of Age and Older)

To demonstrate that the immune responses to the 13 serotypes in 13vPnC (1, 3, 4, 5, 
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by 20vPnC in adults 60 years
of age and older are noninferior to the immune response induced by 13vPnC.

To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 
12F, 15B, 22F, and 33F) induced by 20vPnC in adults 60 years of age and older are
noninferior to the immune response induced by PPSV23.
2.2.1. Primary Immunogenicity Endpoint – Cohort 1 (60 Years of Age and Older)

Serotype-specific OPA titers 1 month after vaccination.
2.3. Secondary Objective – Cohort 2 (50 Through 59 Years of Age) 

To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in 
adults 50 through 59 years of age are noninferior to the immune responses induced by 
20vPnC in adults 60 through 64 years of age.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 26
2.3.1. Secondary Endpoint – Cohort 2 (50 Through 59 Years of Age)
•
Serotype-specific OPA titers 1 month after vaccination.
2.4. Secondary Objective – Cohort 3 (18 Through 49 Years of Age) 
•
To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in 
adults 18 through 49 years of age are noninferior to the immune responses induced by 
20vPnC in adults 60 through 64 years of age.
2.4.1. Secondary Endpoint – Cohort 3 (18 Through 49 Years of Age)
•
Serotype-specific OPA titers 1 month after vaccination.
2.5. Secondary Objective – All Cohorts
•
To describe the immune responses to 20vPnC in adults 60 years of age and older, 
50 through 59 years of age, and 18 through 49 years of age.
2.5.1. Secondary Endpoints – All Cohorts
•
Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
•
4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
•
Serotype-specific OPA titers greater than or equal to the lower limit of quantitation 
(LLOQ) 1 month after vaccination.
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 27
 
3. STUDY DESIGN
This will be a Phase 3, multicenter, randomized, double-blind study that will be conducted 
at investigator sites in the United States and Europe.  Approximately 3880 adults 18 years of 
age and older with no history of pneumococcal vaccination will be enrolled into 1 of 
3 cohorts based on their age at enrollment, and randomized to 1 of 2 vaccine groups 
(20vPnC or control) (Table 3).
Cohort 1: Approximately 3000 subjects will be enrolled into Cohort 1, 2000 subjects will be 
60 through 64 years of age and 1000 subjects will be 65 years of age and older and stratified 
by age. 
 
 Each subject will receive 
either 20vPnC or 13vPnC (control vaccine) at Vaccination 1.  Subjects in Cohort 1 who 
received 20vPnC at Vaccination 1 will receive saline at Vaccination 2.  Subjects in Cohort 1 
who received 13vPnC at Vaccination 1 will receive PPSV23 at Vaccination 2.
Approximately 440 subjects 50 through 59 years of age at enrollment will be assigned to 
Cohort 2, and randomized (3:1) to receive 20vPnC or 13vPnC at Visit 1.
Approximately 440 subjects 18 through 49 years of age at enrollment will be assigned to 
Cohort 3, and randomized (3:1) into 1 of 2 vaccine groups, to receive 20vPnC or 13vPnC at 
Visit 1.
Table 3.
Vaccinations Given to Each Cohort
Cohort
Age 
Vaccination 1 
(Visit 1)
Vaccination 2 
(Visit 2)
N
Cohort 1
60 years of age and older
20vPnC
Saline
1500
13vPnC 
PPSV23
1500
Cohort 2
50 through 59 years of age
20vPnCa
-
330
13vPnCa
-
110
Cohort 3
18 through 49 years of age 
20vPnCa
-
330
13vPnCa
-
110
a.
Single dose on Day 1.
On Day 1 (Visit 1), subjects will be assessed for eligibility, have blood drawn for 
immunogenicity assessments, and receive 20vPnC or 13vPnC.  Subjects will be observed for 
at least 30 minutes after vaccination by blinded site staff, who will record AEs occurring 
during that time.  Subjects will also receive safety follow-up and electronic diary (e-diary) 
instructions at the visit.  Prompted systemic events (fever, headache, fatigue, muscle pain, 
C
C
I
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 28
and joint pain) occurring within 7 days after vaccination and prompted local reactions 
(redness, swelling, and pain at the injection site) occurring at the 20vPnC or 13vPnC 
injection site within 10 days after vaccination will be collected daily in the e-diary.  Use of 
antipyretic/pain medications will be collected daily in an e-diary for 7 days after vaccination.
Subjects in Cohort 1 will return for Visit 2 (28 to 42 days after Visit 1), and information 
will be collected from the subjects on AEs, SAEs, NDCMCs, and e-diary follow-up
(as needed).  Blood will be drawn for immunogenicity assessments.  Saline will be 
administered to subjects who previously received 20vPnC, and PPSV23 will be administered 
to subjects who previously received 13vPnC, by a third-party unblinded site staff member.  
Subjects will be observed for at least 30 minutes after vaccination by blinded site staff, who 
will record AEs occurring during that time.  Subjects will also be reminded about safety 
follow-up.
The subjects in Cohort 1 will then return for Visit 3 (28 to 42 days after Visit 2), and 
information will be collected from the subjects on AEs, SAEs, and NDCMCs.  Blood will be 
drawn for immunogenicity assessments.
Subjects in Cohorts 2 and 3 will return for Visit 2 (28 to 42 days after Visit 1), and 
information will be collected from the subjects on AEs, SAEs, NDCMCs, and e-diary 
follow-up (as needed).  Blood will be drawn for immunogenicity assessments.
Cohorts 1, 2, and 3 will have a final visit, approximately 6 months (168 to 196 days) after 
Visit 1; for this visit, the sites will contact the subject in all cohorts via telephone to inquire 
about SAEs, NDCMCs, and nonstudy vaccinations, as well as concomitant medications used 
to treat SAEs or NDCMCs.
The applicable control groups for the assessments of the 20vPnC group for each cohort are
summarized in Table 4.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 29
Table 4.
Applicable Control Groups for Safety and Immunogenicity Assessments –
Cohorts 1, 2, and 3
Cohort 1 
Investigational
Control 
20vPnC
13vPnCa
PPSV23b
Prompted local reactions
X
(10 days after Visit 1)
X
(10 days after Visit 1)
-
Prompted systemic events
X
(7 days after Visit 1)
X
(7 days after Visit 1)
-
Adverse eventsc
X
(1 month after Visits 1 and 2)
X
(1 month after Visit 1)
X
(1 month after Visit 2)
Immune responses to the 
13vPnC serotypes: 1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, 23F
X  
(1 month after Visit 1)
X
(1 month after Visit 1)
-
Immune responses to the 
additional 7 serotypes: 8, 
10A, 11A, 12F, 15B, 22F, 
33F
X
(1 month after Visit 1)
--
X
(1 month after Visit 2)
Cohort 2 and Cohort 3
Investigational
Control 
20vPnC
13vPnC
Prompted local reactions
X
(10 days after Visit 1)
X
(10 days after Visit 1)
Prompted systemic events
X
(7 days after Visit 1)
X
(7 days after Visit 1)
Adverse eventsc
X
(1 month after Visit 1)
X
(1 month after Visit 1)
Immune responses to the 
13vPnC serotypes: 1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, 23F
X
(1 month after Visit 1 - comparison is to 
subjects 60 through 64 years of age in Cohort 1 
20vPnC group 1 month after vaccination)
--
Immune responses to the 
additional 7 serotypes: 8, 
10A, 11A, 12F, 15B, 22F, 
33F
X
(1 month after Visit 1 - comparison is to 
subjects 60 through 64 years of age in Cohort 1 
20vPnC group 1 month after vaccination)
--
a.
Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV23 at 
Visit 2.
b.
Control group after vaccination with PPSV23 at Visit 2.
c.
SAEs and newly diagnosed chronic medical conditions (NDCMCs) will be collected through 6 months 
after Visit 1.
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 30
3.1. Duration of Subject Participation
Each subject will participate in the study for approximately 6 months.
3.2. Duration of the Study
Based on a 6-month enrollment period, the study duration will be approximately 12 months.
3.3. Number of Subjects
Approximately 3880 subjects will be enrolled to achieve a target of 3492 evaluable subjects 
(assuming a 10% dropout rate).  Of these, 3000 will be 60 years of age and older (Cohort 1), 
440 will be 50 through 59 years of age (Cohort 2), and 440 will be 18 through 49 years of 
age (Cohort 3).
Subjects who withdraw or are withdrawn from the study after randomization will not be 
replaced, regardless of the reason for withdrawal.
4. SUBJECT ELIGIBILITY CRITERIA 
This study can fulfill its objectives only if appropriate subjects are enrolled.  The following 
eligibility criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility should be reviewed and documented by an appropriate member of the 
investigator’s study team before subjects are included in the study.
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study:
1. Evidence of a personally signed and dated informed consent document (ICD) indicating 
that the subject has been informed of all pertinent aspects of the study.
2. Willing and able to comply with scheduled visits, treatment plan, and other study 
procedures.
3. Expected to be available for the duration of the study and can be contacted by telephone 
during study participation.
4. Cohort 1: Male or female adults 60 years of age and older.
Cohort 2: Male or female adults 50 through 59 years of age.
Cohort 3: Male or female adults 18 through 49 years of age.
5. Adults determined by clinical assessment, including medical history and clinical 
judgment, to be eligible for the study, including adults with preexisting stable disease, 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 31
defined as disease not requiring significant change in therapy in the previous 6 weeks or 
hospitalization for worsening disease within 12 weeks before receipt of investigational 
product.
6. Cohort 1 only: Female subject of nonchildbearing potential or male subject not able to 
father children; male subject who is able to father children and willing to use a highly 
effective method of contraception as outlined in this protocol until at least 28 days after 
the last dose of investigational product.
Cohorts 2 and 3 only: Female subject of childbearing potential or male subject who is 
able to father children, and willing to use a highly effective method of contraception as 
outlined in this protocol for at least 28 days after the last dose of investigational product; 
or female subject not of childbearing potential or male subject not able to father children.
 
4.2. Exclusion Criteria
Subjects with any of the following characteristics/conditions will not be included in the 
study:
1. Investigator site staff members directly involved in the conduct of the study and their 
family members, site staff members otherwise supervised by the investigator, or subjects 
who are Pfizer employees, including their family members, directly involved in the 
conduct of the study.
2. Participation in other studies involving investigational drug(s), investigational vaccines, 
or investigational devices within 28 days prior to study entry and/or during study 
participation.  Participation in purely observational studies is acceptable.
3. Previous vaccination with any licensed or investigational pneumococcal vaccine, or 
planned receipt through study participation.
4. History of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaphylaxis) to any component of 20vPnC, 13vPnC, or any other diphtheria 
toxoid–containing vaccine or PPSV23.
5. Serious chronic disorder including metastatic malignancy, severe chronic obstructive 
pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with 
or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the 
investigator’s opinion, excludes the subject from participating in the study.
6. Other acute or chronic medical or psychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or laboratory abnormality that may increase 
the risk associated with study participation or investigational product administration or 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 32
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the subject inappropriate for entry into this study.
7. History of microbiologically proven invasive disease caused by S pneumoniae.
8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic 
agents or systemic corticosteroids, or planned receipt through the last blood draw.  If 
systemic corticosteroids have been administered short term (<14 days) for treatment of an 
acute illness, subjects should not be enrolled into the study until corticosteroid therapy 
has been discontinued for at least 28 days before investigational product administration.  
Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are 
permitted.
9. Subjects with known or suspected immunodeficiency or other conditions associated with 
immunosuppression, including, but not limited to, immunoglobulin class/subclass 
deficiencies, generalized malignancy, human immunodeficiency virus (HIV) infection, 
leukemia, lymphoma, or organ or bone marrow transplant.
10. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
11. Receipt of blood/plasma products or immunoglobulin, from 60 days before 
investigational product administration, or planned receipt through study participation.
12. Pregnant female subjects or breastfeeding female subjects (known or suspected).
4.3. Temporary Delay Criteria
The following conditions are temporary or self-limiting and a subject may be vaccinated 
and/or have blood drawn in the study once the condition(s) has/have resolved and no other 
exclusion criteria are met.
The blood draws prior to Vaccination 1 (all cohorts) and Vaccination 2 (Cohort 1 only) 
should take place on the same day as the vaccination.
4.3.1. Criteria for Temporarily Delaying Vaccine Administration

Current febrile illness (body temperature 100.4F [38C]) or other acute illness within 
48 hours before investigational product administration.

Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live 
vaccine within 28 days before investigational product administration.

Receipt of short-term (<14 days) systemic corticosteroids. Investigational product 
administration should be delayed until systemic corticosteroid use has been discontinued 
for at least 28 days.  Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 33
4.3.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw
•
Receipt of antibiotic therapy within 72 hours before blood draw.
4.4. Lifestyle Requirements
4.4.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods 
 and will confirm that the participant has been instructed in its consistent 
and correct use.  At time points indicated in the Schedule of Activities (SoA), the investigator 
or designee will inform the participant of the need to use highly effective contraception 
consistently and correctly and document the conversation and the participant’s affirmation in 
the participant’s chart (participants need to affirm their consistent and correct use of at least 
1 of the selected methods of contraception).  In addition, the investigator or designee will 
instruct the participant to call immediately if the selected contraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner.
4.5. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study contact list located in the supporting study documentation.
To facilitate access to appropriately qualified medical personnel on study-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigator site, and contact details for a contact center in the 
event that the investigator site staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study.  The contact number can also be used by investigator 
staff if they are seeking advice on medical questions or problems; however, it should be used 
only in the event that the established communication pathways between the investigator site 
and the study team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathways between the investigator site and the study team for 
advice on medical questions or problems that may arise during the study. The contact 
number is not intended for use by the subject directly, and if a subject calls that number, he 
or she will be directed back to the investigator site.
5. INVESTIGATIONAL PRODUCTS
For the purposes of this study, and per International Council for Harmonisation (ICH) 
guidelines, investigational product is defined as a pharmaceutical form of an active
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33).
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 34
For this study, the investigational products are 20vPnC, 13vPnC, PPSV23, and saline.
5.1. Allocation to Investigational Product
Allocation of subjects to vaccine groups will proceed through the use of an interactive 
response technology (IRT) system (interactive Web-based response [IWR]).  The site 
personnel will be required to enter or select information including but not limited to the 
user’s identification (ID) and password, the protocol number, and the subject number. The 
site personnel will then be provided with a randomization number and dispensable unit (DU) 
or container number when investigational product is being supplied via the IRT system.  The 
IRT system will provide a confirmation report containing the subject number, randomization 
number, and DU or container number assigned. The confirmation report must be stored in 
the site’s files.
The study-specific IRT reference manual will provide the contact information and further 
details on the use of the IRT system.
5.2. Blinding of Site Personnel
Site personnel taking part in any subject randomization, assessments, interviews, data 
collection, or case report form (CRF) data entry, including the principal investigator (PI), will 
be blinded to investigational product assignments during the study.
Vaccination 1 will be administered in a double-blind fashion, as the appearance and prefilled 
syringes of 20vPnC and 13vPnC are identical (prefilled syringes packaged in blinded 
cartons).
At Vaccination 2 (Cohort 1 only), saline and PPSV23 will be prepared and administered by a 
third-party unblinded site staff member.  All other study personnel including the PI, and the 
subject, will be blinded. The unblinded site staff member(s) will not participate in subject 
assessments.
The PI will assign the responsibility of administering saline and PPSV23 to third-party 
unblinded site staff who will not participate in the evaluation of any study subject.  More 
than 1 unblinded site staff member will be assigned.  A member of the study site staff or 
clinic pharmacy should fulfill this role.  Contact between the unblinded staff member who 
will administer saline and PPSV23 and study subjects should be kept to a minimum.
5.3. Blinding of the Sponsor
Sponsor personnel directly involved in evaluating subject data will be blinded
 
 
following the principles outlined in ICH E9 guideline on Statistical Principles for Clinical 
Trials.71 A data blinding plan will be created to describe the blinding requirements and 
unblinding events. 
 
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 35
Laboratory personnel performing the immunologic assays will be blinded until the database 
has been locked and unblinded.
5.4. Breaking the Blind
The study will be subject and investigator blinded.
At the initiation of the study, the investigator site will be instructed on the method for 
breaking the blind for an individual subject.  The method will be an electronic process.  
Blinding codes should be broken only in exceptional circumstances when knowledge of the 
actual treatment code is absolutely essential for further management of the subject.  
Investigators are encouraged to discuss with a member of the study team if they believe that 
unblinding is necessary.  When the blinding code is broken, the reason must be fully 
documented and entered on the CRF.
5.5. Subject Compliance
All doses of investigational product will be administered by the appropriately designated 
study staff at the investigator site.
5.6. Investigational Product Supplies
20vPnC, 13vPnC, PPSV23, and saline will be provided by the sponsor to the study sites.
Study vaccines will be packed and labeled as investigational product in accordance with 
current guidelines and applicable local and legal regulatory requirements.  The formulation 
of the investigational products is described below.
5.6.1. Dosage Form(s) and Packaging
20vPnC contains saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 
10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually conjugated to 
CRM197. 
 
 
 
13vPnC contains saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, and 23F individually conjugated to CRM197.  
 
 
 
 
 
 
 
 
 
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 36
20vPnC and 13vPnC will be supplied to the site as packaged, single-use prefilled syringes 
and labeled according to local regulatory requirements.
PPSV23 is a licensed commercial product and is a clear, sterile solution consisting of a 
mixture of purified capsular polysaccharides from 23 serotypes of S pneumoniae: 1, 2, 3, 4, 
5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.  
The vaccine is formulated to contain 25 g of each of the 23 purified polysaccharide 
serotypes per 0.5-mL dose of vaccine in an isotonic saline solution containing 0.25% phenol 
as a preservative.  PPSV23 will be supplied by the sponsor to the site as packaged vials and 
labeled according to local regulatory requirements.
The placebo will consist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection) and will be supplied to the site as packaged vials and labeled according to 
local regulatory requirements.
5.6.2. Preparation and Dispensing
See the Investigational Product Manual (IP manual) or package insert for instructions on how 
to prepare the investigational product for administration.  Investigational product should be 
prepared and dispensed by an appropriately qualified and experienced member of the study 
staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy 
assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance.
Investigational product will be prepared by qualified site personnel according to the IP
manual.  The investigational product will be administered to blinded subjects.
5.7. Administration
At Vaccination 1, a 0.5-mL dose of 20vPnC or 13vPnC will be administered intramuscularly 
in the deltoid muscle of the nondominant arm by a blinded site staff member (20vPnC and 
13vPnC have the same appearance).
At Vaccination 2 (Cohort 1 only), a 0.5-mL dose of saline or PPSV23 will be prepared and 
administered by third-party unblinded site staff member(s) and will be administered 
intramuscularly in the deltoid muscle of the nondominant arm to blinded subjects.  All other 
study personnel including the principal investigator, and the subject, will be blinded. The 
unblinded site staff members will not participate in subject assessments.
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of investigational products should be performed by an appropriately 
qualified, Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the 
study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as allowed by local, state, and institutional guidance.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 37
Investigational product administration details will be recorded on the CRF.
5.8. Investigational Product Storage
The investigator or an approved representative, eg, pharmacist, unblinded 
dispenser/administrator, will ensure that all investigational products, including any 
comparator and/or marketed products, are stored in a secured area with controlled access 
under required storage conditions and in accordance with applicable regulatory requirements.
Investigational products should be stored in their original containers and in accordance with 
the labels.
20vPnC, 13vPnC, PPSV23, and saline will be shipped to the study site after required 
regulatory and legal documents have been received by the sponsor.
 
 
Any storage conditions stated in the SRSD (20vPnC IB, 13vPnC USPI, and PPSV23 USPI)
will be superseded by the storage conditions stated on the product label.
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room-temperature products).  This should 
be captured from the time of investigational product receipt throughout the study.  Even for 
continuous-monitoring systems, a log or site procedure that ensures active evaluation for 
excursions should be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business day to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability to store or view the minimum/maximum 
temperature for all nonworking days upon return to normal operations.  The operation of the 
temperature-monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularly inspected to ensure they are maintained in working order.
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery.  The site should actively pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible.  Deviations from the storage 
requirements, including any actions taken, must be documented and reported to Pfizer.
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 38
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefly out of the temperature range described in the labeling are not 
considered excursions.
5.9. Investigational Product Accountability
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  All investigational products will be 
accounted for using a drug accountability form/record.
Used needles and syringes should be disposed of according to local practice.  Empty outer 
investigational product containers must be retained until reviewed by the sponsor's 
representative and then may be destroyed after the sponsor’s representative has performed 
accountability.  Investigational product return/destruction must be documented on the 
accountability log.
5.9.1. Destruction of Investigational Product Supplies
The sponsor or designee will provide guidance on the destruction of unused investigational
product (eg, at the site).  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroyed in compliance with applicable 
environmental regulations, institutional policy, and any special instructions provided by 
Pfizer, and all destruction must be adequately documented.
5.10. Concomitant Treatment(s)
5.11. Prohibited Concomitant Treatments

Receipt of any investigational vaccines, drugs, or medical devices is prohibited during 
subject participation in the study.

Receipt of nonstudy pneumococcal vaccine is prohibited during subject participation in 
the study.

Receipt of blood/plasma products, immunoglobulins, and/or immunosuppressive therapy 
(including a 14-day course of systemic corticosteroids) is prohibited during study 
participation.
5.12. Permitted Concomitant Treatments

Prescription and nonprescription medications, vitamins, minerals, and herbal remedies 
are permitted during subject participation in the study.

Licensed inactivated influenza vaccine may be given >14 days prior to or >14 days after 
investigational product administration (Visit 1 or Visit 2 for Cohort 1, or Visit 1 for 
Cohorts 2 and 3).  If medically necessary (eg, pandemic), influenza vaccine may be given 
at any time.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 39

Receipt of other licensed nonstudy vaccine (except pneumococcal [prohibited] or 
influenza vaccine [permitted] as described above) is permitted after Visit 3 (Cohort 1 
only) or after Visit 2 (Cohorts 2 and 3).

The use of prophylactic antipyretic medication, while permitted, is not recommended on 
the day prior to vaccination or the day of investigational product administration.

Inhaled/nebulized, topical (skin, eyes, or ears), or localized injections of corticosteroids 
(eg, intra-articular or intrabursal administration) are permitted during subject 
participation in the study.
5.13. Recording Concomitant Treatments
The name and date of administration for any nonstudy vaccinations received from the time of 
signing of the ICD to the final visit will be collected and recorded in the CRF.
Details of any medications that the subject is currently taking for medical conditions at 
enrollment will be recorded in the CRF.
Medications taken to treat SAEs or NDCMCs from the time of signing of the ICD to the final 
visit will be recorded in the CRF.
6. STUDY PROCEDURES
The study procedures are summarized in the Schedule of Activities (Table 1 and Table 2). 
The day of vaccination is considered to be Day 1.
6.1. Cohort 1
6.1.1. Cohort 1: Visit 1 (Vaccination 1 – Day 1)
Prior to vaccination:

Obtain written informed consent before performing any study-specific procedures.

Assign a subject number via the IRT.

Obtain and record the subject demography (sex, date of birth, ethnicity, and race). The 
complete date of birth (ie, DD-MMM-YYYY) will be collected to critically evaluate the 
immune response and safety profile by age.

Obtain and record the medical history including the presence of chronic conditions 
(eg, diabetes, asthma, cardiac disease, COPD) and/or medical history of significance such 
as relevant surgical procedures.

Assess and record smoking history.

Record details of any medications currently being taken for any medical conditions.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 40

Record nonstudy vaccinations and medications as described in Section 5.13.

Measure and record the subject’s height, weight, and oral temperature (F/C).

Conduct a clinical assessment. If the clinical assessment indicates that a physical 
examination is necessary to comprehensively evaluate the subject, perform a physical 
examination and record any findings in the source documents and, if significant, record 
on the medical history CRF.

Instruct the subject to use appropriate contraceptives until 28 days after Vaccination 2, if 
applicable, and document the conversation and the subject’s affirmation in the subject’s 
chart.

Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary delay criteria are met. 

Assign a randomization number and an investigational product container number via the 
IRT.  This must be the last step before proceeding.  A site staff member will prepare the 
investigational product according to the IP manual.
After randomization:

Collect a blood sample of approximately 50 mL for immunogenicity assessments prior to 
vaccination.

Administer a single 0.5-mL injection of investigational product into the deltoid muscle of 
the nondominant arm.
After vaccination:

Blinded site staff will observe the subject for at least 30 minutes after investigational 
product administration for any acute (immediate) reactions.  Record any acute 
(immediate) reactions on the AE CRF and on an SAE form as applicable.

Issue the subject a measuring device to measure injection site reactions and a digital 
thermometer and provide instructions on their use.

Issue the subject an e-diary and provide instructions on its use and completion.  Ask the 
subject to complete the e-diary from Day 1 to Day 10, with Day 1 being the day of 
vaccination.

Ask the subject to contact the site staff or investigator immediately during the 10 days 
after vaccination if he or she experiences redness or swelling at the injection site 
measuring >20 measuring device units (>10.0 cm) or severe injection site pain (prevents 
daily activity) to determine if the event requires further assessment by the investigator.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 41

Subjects will also be instructed to contact site staff or the investigator if they experience 
any possible Grade 4 prompted local reaction or systemic event (refer to Section 6.3).

Inform the subject that use of prophylactic antipyretic/pain medication, while permitted, 
is not recommended on the day of investigational product administration (before or after 
vaccination).

Ask the subject to contact the site staff or investigator immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the 
study period.

Remind the subject to use appropriate contraceptives until 28 days after Vaccination 2, if 
applicable.

Record AEs, SAEs, and NDCMCs as described in Section 8.1.4.

The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability records.

The investigator or appropriately qualified designee reviews the e-diary data online at 
frequent intervals for the 10 days following vaccination to evaluate subject compliance 
and as part of the ongoing safety review.
6.1.2. Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)
Prior to vaccination:

Record nonstudy vaccinations and medications as described in Section 5.13.

Measure and record the subject’s oral temperature (F/C).

Perform a contraception check (see Section 4.4.1), if applicable.

Ensure and document that the subject continues to be eligible for the study and that none 
of the temporary delay criteria are met.

Review the subject’s e-diary data and collect e-diary.  Collect stop dates of any e-diary 
events ongoing on the last day that the e-diary was completed and record stop dates in the 
CRF.

Determine if any AEs, SAEs, or NDCMCs have occurred since Visit 1 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described in 
Section 8.1.4.

Collect a blood sample of approximately 50 mL for immunogenicity assessments prior to 
vaccination.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 42

An unblinded site staff member will administer a single 0.5-mL injection of PPSV23 or 
saline into the deltoid muscle of the nondominant arm.
After vaccination:

Blinded site staff will observe the subject for at least 30 minutes after investigational 
product administration for any acute (immediate) reactions.  Record any acute 
(immediate) reactions on the AE CRF and on an SAE form as applicable.

Ask the subject to contact the site staff or investigator immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the 
study period.

Remind the subject to use appropriate contraceptives until 28 days after vaccination, if 
applicable.

The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability records.
6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)

Record nonstudy vaccinations and concomitant medications as described in Section 5.13.

Perform a contraception check (see Section 4.4.1), if applicable .

Ensure and document that the subject continues to be eligible for the study and that none 
of the temporary blood draw delay criteria are met.

Determine if any AEs, SAEs, or NDCMCs have occurred since Visit 2 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described in 
Section 8.1.4.

Collect a blood sample of approximately 50 mL for immunogenicity assessments.

Remind the subject to contact the site staff or investigator immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the 
study period.

The investigator or an authorized designee completes the CRF.
6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] – 168 to 196 
Days After Vaccination 1)

Record nonstudy vaccinations and medications as described in Section 5.13.

Determine whether any NDCMCs or SAEs have occurred since Visit 3 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 43
(ie, record stop dates or confirm if they are still continuing) and record as described in 
Section 8.1.4.

The investigator or an authorized designee completes the CRF.
6.2. Cohorts 2 and 3
6.2.1. Cohorts 2 and 3: Visit 1 (Vaccination – Day 1)
Prior to vaccination:

Obtain written informed consent before performing any study-specific procedures.

Assign a subject number via the IRT.

Obtain and record the subject demography (sex, date of birth, ethnicity, and race). The 
complete date of birth (ie, DD-MMM-YYYY) will be collected to critically evaluate the 
immune response and safety profile by age.

Obtain and record the medical history including the presence of chronic conditions 
(eg, diabetes, asthma, cardiac disease, COPD) and/or medical history of significance such 
as relevant surgical procedures.

Assess and record smoking history.

Record details of any medications currently being taken for any medical conditions

Record nonstudy vaccinations and medications as described in Section 5.13.

Measure and record the subject’s height, weight, and oral temperature (F/C).

Conduct a clinical assessment.  If the clinical assessment indicates that a physical 
examination is necessary to comprehensively evaluate the subject, perform a physical 
examination and record any findings in the source documents and, if significant, record 
on the medical history CRF.

Instruct the subject to use appropriate contraceptives until 28 days after vaccination, if 
applicable, and document the conversation and the subject’s affirmation in the subject’s 
chart.

Perform urine pregnancy test for female subjects of childbearing potential 
(see Section 7.1).

Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary delay criteria are met.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 44

Assign a randomization number and an investigational product container number via the 
IRT.  This must be the last step before proceeding.  A site staff member will prepare the 
investigational product according to the IP manual.
After randomization:

Collect a blood sample of approximately 50 mL for immunogenicity assessments prior to 
vaccination.

Administer a single 0.5-mL injection of investigational product into the deltoid muscle of 
the nondominant arm.
After vaccination:

Blinded site staff will observe the subject for at least 30 minutes after investigational 
product administration for any acute (immediate) reactions.  Record any acute 
(immediate) reactions on the AE CRF and on an SAE form as applicable.

Issue the subject a measuring device to measure injection site reactions and a digital 
thermometer and provide instructions on their use.

Issue the subject an e-diary and provide instructions on its use and completion.  Ask the 
subject to complete the e-diary from Day 1 through Day 10, with Day 1 being the day of 
vaccination.

Ask the subject to contact the site staff or investigator immediately during the 10 days 
after vaccination if he or she experiences redness or swelling at the injection site 
measuring >20 measuring device units (>10.0 cm) or severe injection site pain (prevents 
daily activity) to determine if the event requires further assessment by the investigator.

Subjects will also be instructed to contact site staff or the investigator if they experience 
any possible Grade 4 prompted local reaction or systemic event (refer to Section 6.3).

Inform the subject that use of prophylactic antipyretic/pain medication, while permitted, 
is not recommended on the day of investigational product administration (before or after 
vaccination).

Ask the subject to contact the site staff or investigator immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the 
study period.

Remind the subject to use appropriate contraceptives until 28 days after vaccination, if 
applicable.

Record AEs, SAEs, and NDCMCs as described in Section 8.1.4.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 45

The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability records.

The investigator or appropriately qualified designee reviews the e-diary data online at 
frequent intervals for the 10 days following vaccination to evaluate subject compliance 
and as part of the ongoing safety review.
6.2.2. Cohorts 2 and 3: Visit 2 (Follow-up – 28 to 42 Days After Visit 1)

Record nonstudy vaccinations and concomitant medications as described in Section 5.13.

Perform a contraception check (see Section 4.4.1), if applicable.

Ensure and document that the subject continues to be eligible for the study and that none 
of the temporary blood draw delay criteria are met.

Review the subject’s e-diary data and collect the e-diary.  Collect stop dates of any 
e-diary events ongoing on the last day that the e-diary was completed and record stop 
dates in the CRF.

Determine if any AEs, SAEs, or NDCMCs have occurred since Visit 1 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described in 
Section 8.1.4.

Collect a blood sample of approximately 50 mL for immunogenicity assessments.

Remind the subject to contact the site staff or investigator immediately if any significant 
illness or medical event (eg, emergency room visit or hospitalization) occurs during the 
study period.

The investigator or an authorized designee completes the CRF.
6.2.3. Cohorts 2 and 3: Visit 3 (6-Month Safety Collection [Telephone Contact] – 168 to 
196 Days After Vaccination 1)

Record nonstudy vaccinations and medications as described in Section 5.13.

Determine whether any NDCMCs or SAEs have occurred since Visit 2 and follow up on 
any previously reported ongoing AEs, SAEs, or NDCMCs to determine the outcome 
(ie, record stop dates or confirm if they are still continuing) and record as described in 
Section 8.1.4.

The investigator or an authorized designee completes the CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 46
6.3. Unscheduled Visits (All Cohorts)
Following vaccination (Vaccination 1 in Cohort 1), if the subject reports redness or swelling 
at the injection site measuring >20 measuring device units (>10.0 cm) or severe injection site 
pain during the 10 days following vaccination, a telephone contact must occur as soon as 
possible between the investigator or medically qualified designee and the subject to assess if 
an unscheduled site visit is required.  A site visit must be scheduled as soon as possible to 
assess the extent of the reaction unless any of the following is true:

The subject is unable to attend the unscheduled visit.

The reaction is no longer present at the time of the telephone contact.

The subject recorded an incorrect value in the e-diary (confirmation of an e-diary data 
entry error).

The PI or authorized designee determined it was not needed.
This telephone contact will be recorded in the subject’s source documentation and the CRF.
If the subject is unable to attend the unscheduled visit, or the PI or authorized designee 
determined it was not needed, any ongoing reactions must be assessed at the next study visit.
During the unscheduled visit, the reactions should be assessed by the investigator or a 
medically qualified member of the study staff such as a study physician or a study nurse, as 
applicable to the investigator’s local practice, who will:

Measure oral temperature (F/C).

Measure minimum and maximum diameters of redness (if present).

Measure minimum and maximum diameters of swelling (if present).

Assess injection site pain (if present) in accordance with the grades provided in 
Section 7.2.2.1.

Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The investigator or an authorized designee will complete the unscheduled visit assessment 
page of the CRF.
Subjects will also be instructed to contact site staff or the investigator if they experience any 
possible Grade 4 prompted systemic event (ie, emergency room visit or hospitalization for 
headache, fatigue, muscle pain, or joint pain) or local reaction (ie, necrosis, exfoliative 
dermatitis, or emergency room visit/hospitalization for injection site pain) within 7 or 
10 days, respectively, after vaccination.  Lastly, subjects will be instructed to contact site 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 47
staff or the investigator to report any significant illness, medical event, or hospitalization that 
occurs during the study period.  The site should determine if an unscheduled visit to further 
evaluate the event is warranted in all such cases.
6.4. Subject Withdrawal
An investigator and/or sponsor can withdraw a subject from the study if deemed appropriate.  
In addition, if a subject fails to continue to meet the inclusion criteria, new information 
becomes available that would exclude the subject, or the subject develops a condition or 
situation that would meet exclusion criteria, the subject may be considered for withdrawal.
Reasons why a subject may discontinue or be withdrawn from the study by the investigator 
or sponsor include, but are not limited to, failure to meet entrance criteria (screening failure), 
AE, death, pregnancy, protocol deviation, lost to follow-up, no longer willing to participate 
in the study, study terminated by the sponsor, or any other reason.  Subjects who have 
received the investigational product will not be replaced, regardless of the reason for 
withdrawal.
The investigator should capture the reason for withdrawal in the database for all subjects, and 
a follow-up telephone contact 6 months after Vaccination 1 for the collection of safety 
information should be completed for all subjects who have been withdrawn after 
administration of investigational product unless consent for further contact has been 
withdrawn.
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or sponsor for safety (see also 
Section 8.1.3) or behavioral reasons, or the inability of the subject to comply with the 
protocol-required schedule of study visits or procedures at a given study site.
If a subject does not return for a scheduled visit, every effort should be made to contact the 
subject.  All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In any circumstance, every effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the subject return for a final visit, if applicable, 
and follow up with the subject regarding any unresolved adverse events (AEs).
If the subject withdraws from the study, and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent.
Withdrawal of Consent
Subjects who request to discontinue receipt of investigational product will remain in the 
study and must continue to be followed for protocol specified follow-up procedures through 
6 months after the first vaccination.  The only exception to this is when a subject specifically 
withdraws consent for any further contact with him or her or persons previously authorized 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 48
by the subject to provide this information.  Subjects should notify the investigator in writing 
of the decision to withdraw consent from future follow-up, whenever possible.  The 
withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is only from further receipt of investigational 
product or also from study procedures and/or study follow-up, and entered on the appropriate 
CRF page.  In the event that vital status (whether the subject is alive or dead) is being 
measured, publicly available information should be used to determine vital status only as 
appropriately directed in accordance with local law.
Lost to Follow-up
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status.  This includes follow-up with persons authorized by the subject as noted above.  Lost 
to follow-up is defined by the inability to reach the subject after a minimum of 2 documented 
phone calls, faxes, or emails as well as lack of response by the subject to 1 registered mail 
letter.  All attempts should be documented in the subject’s medical records.  If it is 
determined that the subject has died, the site will use locally permissible methods to obtain 
the date and cause of death.  If the investigator’s use of a third-party representative to assist 
in the follow-up portion of the study has been included in the subject’s informed consent, 
then the investigator may use a sponsor-retained third-party representative to assist site staff 
with obtaining the subject’s contact information or other public vital status data necessary to 
complete the follow-up portion of the study.  The site staff and representative will consult 
publicly available sources, such as public health registries and databases, in order to obtain 
updated contact information.  If, after all attempts, the subject remains lost to follow-up, then 
the last-known-alive date as determined by the investigator should be reported and 
documented in the subject’s medical records.
7. ASSESSMENTS
Every effort should be made to ensure that the protocol-required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside of the control of the investigator that may make it unfeasible to 
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safety and well-being of the subject.  When a protocol-required test cannot be performed, the 
investigator will document the reason for this and any corrective and preventive actions that 
he or she has taken to ensure that normal processes are adhered to as soon as possible.  The 
study team will be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
7.1. Pregnancy Testing
For female subjects of childbearing potential, a urine pregnancy test, with sensitivity of at 
least 25 mIU/mL, will be performed immediately before administration of the investigational 
product.  A negative pregnancy test result is required before the subject may receive the 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 49
investigational product.  Pregnancy tests may also be repeated if requested by institutional 
review boards (IRBs)/ethics committees (ECs) or if required by local regulations.  In the case 
of a positive confirmed pregnancy at Visit 1, the subject will be withdrawn from 
administration of investigational product and from the study.
7.2. Safety Parameters
Safety parameters will be assessed as described in the Schedule of Activities (Table 1 and 
Table 2), Section 6, and below.
A clinical assessment, including medical history and measurement of oral temperature, will 
be performed on all subjects prior to vaccination to determine subject eligibility and to 
establish a clinical baseline.  Significant medical history, significant findings from any 
physical examination, if performed, and temperature measurements will be documented and 
recorded in the source documents and/or the CRF.
Acute reactions (immediate events) within the first 30 minutes after investigational product 
administration will be assessed and documented as an AE or SAE, as appropriate, in the 
CRF.
Prompted e-diary events, including local reactions and systemic events that occur 10 and 
7 days, respectively, after investigational product administration, are graded as described in 
Section 7.2.2. Furthermore, AEs, SAEs, and NDCMCs will be collected as defined in 
Section 8.1.4.
7.2.1. Subject Electronic Diary
The subject will be asked to monitor and record local reactions for 10 days, and systemic 
events, fever, and antipyretic/pain medication usage for 7 days, each evening following 
vaccination (Vaccination 1 in Cohort 1) (Day 1 through Day 10 or Day 7, where Day 1 is the 
day of vaccination) using an e-diary. This allows recording of these assessments only within 
a fixed time window, thus providing the accurate representation of the subject’s experience at 
that time.  Data on local reactions, specific systemic events, fever, and antipyretic/pain 
medication usage reported on the e-diary will be transferred electronically to the e-diary 
vendor, where they will be available for review by investigators, their appropriately qualified 
designees, and sponsor staff at all times via an internet-based portal.  At intervals agreed to 
by the vendor and Pfizer, these data will be transferred electronically to Pfizer for analysis 
and reporting.
The daily e-diary data will not be captured in the CRF.  However, if a subject withdraws 
because of prompted events reported in the e-diary, the event(s) should be recorded on the 
AE page of the CRF, regardless of whether the investigator considers the event(s) to be 
clinically significant.
The investigators (or appropriately qualified designees) are required to review the e-diary 
data online at frequent intervals to evaluate subject compliance and reported events as part of 
the ongoing safety review.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 50
The investigator or designee must obtain stop dates for any reactions ongoing on the last day 
that the e-diary was completed.  The stop dates should be entered in the CRF.
7.2.2. Grading Scale for Prompted Events
The grading scales used in this study to assess AEs as described below are based on concepts 
outlined in the Food and Drug Administration (FDA) Center for Biologics Evaluation and 
Research (CBER) guidelines on toxicity grading scales for healthy adult volunteers enrolled 
in preventive vaccine clinical trials.72
7.2.2.1. Local Reactions 
From Day 1 through Day 10 after vaccination (Vaccination 1 in Cohort 1), where Day 1 is 
the day of vaccination, subjects will be asked to assess redness, swelling, and pain at the 
injection site and to record the symptoms in the e-diary in the evening.  Redness and swelling 
will be measured and recorded in measuring device units (range: 1 to 21 and >21), and then 
categorized during analysis as mild, moderate, or severe based on the grading scale in 
Table 5 below.  Measuring device units can be converted to centimeters according to the 
following scale: 1 measuring device unit = 0.5 cm.  Pain at the vaccine injection site will be 
assessed by the subject as mild, moderate, or severe according to the grading scale in 
Table 5.  A subject with a severe (Grade 3 or above) local reaction will be prompted to 
contact the investigator to assess the reaction and perform an unscheduled assessment or visit 
as appropriate.
Only an investigator is able to classify a subject’s local reaction as Grade 4, after physical 
examination of the subject or documentation from another medically qualified source 
(eg, emergency room or hospital record) or, in the case of pain at the injection site only, 
telephone contact with the subject.  If a subject experiences a Grade 4 local reaction, the 
investigator must immediately notify the sponsor.  Site staff will educate the subject 
regarding signs and symptoms that would prompt site contact.  Grade 4 reactions will be 
collected as an AE on the CRF. The event will be graded using the AE severity grading scale 
(Section 8.3).
The procedure for notification of the sponsor is provided in the study reference manual 
(SRM) or equivalent.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 51
Table 5.
Grading Scales for Local Reactions
Mild 
Grade 1
Moderate
Grade 2
Severe
Grade 3a
Grade 4b
Redness
5 to 10 measuring 
device units
=
>2.0 to 5.0 cm
11 to 20 measuring
device units
=
>5.0 to 10.0 cm
>20 measuring 
device units
=
>10.0 cm
Necrosis or 
exfoliative  
dermatitis
Swelling
5 to 10 measuring 
device units
=
>2.0 to 5.0 cm
11 to 20 measuring 
device units
=
>5.0 to 10.0 cm
>20 measuring 
device units
=
>10.0 cm
Necrosis
Pain at injection site
Does not interfere 
with activity
Interferes with 
activity
Prevents daily 
activityc
Emergency room 
visit or 
hospitalization for 
severe injection site 
pain
Abbreviations:  CRF = case report form; e-diary = electronic diary.
Note: If the size of the redness and/or swelling falls between 2 measuring device units, the higher measuring 
device unit number will be recorded in the e-diary.
a.
Subjects experiencing Grade 3 local reactions are required to contact the investigator site. In the event that 
the subject does not call, the investigator will call the subject.
b.
Grade 4 assessment should be made by the investigator; Grade 4 will not be collected in the e-diary but will 
be collected as an AE on the CRF.  The severity of the local reaction should be graded using the AE 
severity grading scale.
c.
Prevents daily activity, eg, results in missed days of work or school or is otherwise incapacitating.
7.2.2.2. Systemic Events
From Day 1 through Day 7 after vaccination (Vaccination 1 in Cohort 1), where Day 1 is the 
day of vaccination, subjects will be asked to assess headache, fatigue, muscle pain, and joint 
pain and to record the symptoms in the e-diary in the evening.  The symptoms will be 
assessed by the subject as mild, moderate, or severe according to the grading scale in Table 6
below.  Subjects will also be instructed to contact site staff or the investigator if they 
experience any possible Grade 4 prompted systemic event (ie, emergency room visit or 
hospitalization for severe headache, severe fatigue, severe muscle pain, or severe joint pain) 
within 7 days after vaccination.  Study staff may also contact the subject to obtain additional 
information on Grade 3 events entered into the e-diary.
Only an investigator is able to classify a subject’s systemic event as Grade 4, after physical 
examination of the subject or documentation from another medically qualified source 
(eg, emergency room or hospital record) or telephone contact with the subject.  If a subject 
experiences a Grade 4 systemic event, the investigator must immediately notify the sponsor.  
Grade 4 events will be collected as an AE on the CRF. The event will be graded using the 
AE severity grading scale (Section 8.3).
The procedure for notification of the sponsor is provided in the SRM or equivalent.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 52
Table 6.
Grading Scales for Systemic Events
Mild
Grade 1
Moderate
Grade 2
Severe
Grade 3a
Grade 4b
Fatigue 
(tiredness)
Does not interfere 
with activity
Some interference 
with activity
Prevents daily routine 
activity
Emergency room visit 
or hospitalization for 
severe fatigue
Headache
Does not interfere 
with activity
Some interference 
with activity
Prevents daily routine 
activity
Emergency room visit 
or hospitalization for 
severe headache
Muscle pain
Does not interfere 
with activity
Some interference 
with activity
Prevents daily routine 
activity
Emergency room visit 
or hospitalization for 
severe muscle pain
Joint pain
Does not interfere 
with activity
Some interference 
with activity
Prevents daily routine 
activity
Emergency room visit 
or hospitalization for 
severe joint pain
Abbreviations: CRF = case report form; e-diary = electronic diary.
a.
Prevents daily routine activity, eg, results in missed days of work or school or is otherwise incapacitating; 
includes use of narcotics for analgesia.
b.
Grade 4 assessment should be made by the investigator; Grade 4 will not be collected in the e-diary but will 
be collected as an AE on the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale in Section 8.3.
7.2.2.3. Fever
In order to record information on fever, a digital thermometer will be given to the subject 
with instructions on how to measure oral temperature at home.  Temperature will be 
collected in the evening daily for 7 days following Vaccination 1 (Days 1 through 7, where 
Day 1 is the day of vaccination) and at any time during the 7 days that fever is suspected.  
Fever is defined as an oral temperature of 100.4F (38.0C).  The highest temperature for 
each day will be recorded in the e-diary.  In the event of a fever on Day 7, temperature will 
be collected daily until fever has resolved (1 day of temperature <100.4F [<38.0C]) in 
order to collect a stop date in the CRF.  Temperature will be measured and recorded to 
1 decimal place and then grouped into ranges for the analysis according to Table 7 below.  
Temperatures reported in degrees Fahrenheit will be programmatically converted to degrees 
Celsius for reporting.
Table 7.
Ranges for Fever
38.0C to 38.4C
>38.4C to 38.9C
>38.9C to 40.0C
>40.0C
Note: Fever is defined as temperature ≥38.0°C.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 53
7.2.2.4. Use of Antipyretic/Pain Medication
The subject will be asked to record the use of antipyretic/pain medication (yes/no) in the 
e-diary in the evening daily for 7 days following Vaccination 1.  The use of prophylactic 
antipyretic/pain medication, while permitted, is not recommended on the day of 
investigational product administration (before or after vaccination).
7.3. Immunogenicity
Blood samples (approximately 50 mL per sample) will be collected from all subjects at 
Visit 1 (prior to administration of 20vPnC or 13vPnC) and at Visit 2 (note this is before 
administration of saline or PPSV23 for subjects in Cohort 1).  Subjects in Cohort 1 will also 
have blood collected at Visit 3.
The total volume of blood collected from each subject in Cohort 1 completing participation 
through Visit 3 will be approximately 150 mL. The total volume of blood collected from 
each subject in Cohort 2 or Cohort 3 completing participation through Visit 2 will be 
approximately 100 mL.
Sample collection, processing, storage, and shipping information can be found in the SRM or 
equivalent manual.
Immunogenicity assays will be performed at Pfizer Vaccine Research & Development 
Laboratory located at 401 North Middletown Road, Pearl River, NY 10965 and/or at an 
external contract laboratory designated by Pfizer.
Pneumococcal Antibody Response
OPA titers for serotypes present in 20vPnC (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 
15B, 18C, 19A, 19F, 22F, 23F, and 33F) will be determined on all sera collected prior to 
study vaccination and 1 month (28 to 42 days) after Vaccination 1 in Cohort 1, and 1 month 
(28 to 42 days) after vaccination in Cohorts 2 and 3.  OPA titers for the 7 additional 
serotypes only (8, 10A, 11A, 12F, 15B, 22F, and 33F) will be determined on sera collected 
1 month (28 to 42 days) after Vaccination 2 in Cohort 1.
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 54
7.4. Biological Samples
Blood samples will be used only for scientific research.  Each sample will be labeled with a 
code so that the laboratory personnel testing the samples will not know the subject’s identity.  
Samples that remain after performing assays outlined in the protocol may be stored by Pfizer.  
Unless a time limitation is required by local regulations or ethical requirements, the samples 
will be stored for up to 15 years after the end of the study and then destroyed.  
 
 
 No testing of 
the subject’s genetic material will be performed.
The subject may request that his or her samples, if still identifiable, be destroyed at any time; 
however, any data already collected from those samples will still be used for this research.  
The biological samples may be shared with other researchers as long as confidentiality is 
maintained and no testing of the subject’s genetic material is performed.
8. ADVERSE EVENT REPORTING
8.1. Requirements
The table below summarizes the requirements for recording safety events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety.  These requirements are delineated for 3 types of events: (1) SAEs; 
(2) nonserious AEs; and (3) exposure to the investigational product under study during 
pregnancy or breastfeeding, and occupational exposure.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE
All
All
Nonserious AE
All
None
Exposure to the 
investigational product 
under study during 
pregnancy or breastfeeding, 
and occupational exposure
All (regardless of whether 
associated with an AE), except 
occupational exposure
Exposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study.  In particular, if the SAE is fatal or life-threatening, 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 55
notification to Pfizer Safety must be made immediately, irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow-up) information on 
previously forwarded reports.  In the rare situation that the investigator does not become 
immediately aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
In addition to the reporting requirements to Pfizer Safety (above), the investigator must 
contact the Pfizer study physician or sponsor designee directly as soon as possible after
becoming aware of an SAE occurring within 30 days after vaccination. Additional 
information regarding such events and the reporting requirements can be found in the SRM 
or equivalent.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causality.  Any information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  In the case of a 
subject death, a summary of available autopsy findings must be submitted as soon as possible 
to Pfizer Safety.  Any pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory data) are to 
be sent to Pfizer Safety ONLY upon request.
As part of ongoing safety reviews conducted by the sponsor, any nonserious AE that is 
determined by the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical 
study.
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  It 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly observed AEs and all AEs spontaneously 
reported by the study subject.  In addition, each study subject will be questioned about the 
occurrence of AEs in a nonleading manner.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 56
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF.
When a subject withdraws from the study because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively eliciting and collecting AEs and SAEs and NDCMCs (“active 
collection period”) for each subject begins from the time the subject provides informed 
consent, which is obtained before the subject’s participation in the study (ie, before 
undergoing any study-related procedure and/or receiving investigational product).
In Cohort 1, AEs will be recorded and reported from the signing of the ICD through Visit 3.
In Cohorts 2 and 3, AEs will be recorded and reported from the signing of the ICD through 
Visit 2.
For all subjects, SAEs and NDCMCs will be recorded and reported from the signing of the 
ICD until the final visit (approximately 6 months after Visit 1). An NDCMC is defined as a 
disease or medical condition, not previously identified, that is expected to be persistent or is 
otherwise long-lasting in its effects.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility of being related to investigational 
product must be reported to Pfizer Safety.
Follow-up by the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 57
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow-up by the investigator may be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causality must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causality assessment is the determination of whether there exists a reasonable 
possibility that the investigational product caused or contributed to an AE; generally the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined by the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearly documented on study records.
In addition, if the investigator determines that an SAE is associated with study procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2. Definitions
8.2.1. Adverse Events
An AE is any untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessarily have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to:

Abnormal test findings;

Clinically significant signs and symptoms;

Changes in physical examination findings;

Hypersensitivity;

Progression/worsening of underlying disease;

Drug abuse;

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 58

Drug dependency.
Additionally, AEs may include signs and symptoms resulting from:

Drug overdose;

Drug withdrawal;

Drug misuse;

Drug interactions;

Extravasation;

Exposure during pregnancy (EDP);

Exposure via breastfeeding;

Medication error;

Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when any of the following 
conditions are met: 

Test result is associated with accompanying symptoms; and/or

Test result requires additional diagnostic testing or medical/surgical intervention; and/or

Test result leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional concomitant drug 
treatment, or other therapy; and/or

Test result is considered to be an AE by the investigator or sponsor.
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any untoward medical occurrence at any dose that:

Results in death;

Is life-threatening (immediate risk of death);

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 59

Requires inpatient hospitalization or prolongation of existing hospitalization;

Results in persistent or significant disability/incapacity (substantial disruption of the 
ability to conduct normal life functions);

Results in congenital anomaly/birth defect.
Or that is considered to be:

An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may not be immediately life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may jeopardize 
the subject or may require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency or drug abuse.
Medical device complaints may meet the SAE reporting requirement criteria (see the Medical 
Device Complaint Reporting Requirements section).  An incident is any malfunction (ie, the 
failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly or indirectly, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deterioration in their state of health.
A serious injury that can cause a serious deterioration in state of health can include:

A life-threatening illness, even if temporary in nature;

A permanent impairment of a body function or permanent damage to a body structure;

A condition necessitating medical or surgical intervention to prevent the above 2 bulleted 
items;
Examples: clinically relevant increase in the duration of a surgical procedure; a condition 
that requires hospitalization or significant prolongation of existing hospitalization;

Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the manufacturer’s instructions for use;

Fetal distress, fetal death, or any congenital abnormality or birth defects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 60
8.2.4. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility, or any prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric 
wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a 
tuberculosis unit).  An emergency room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency room visit is assessed for medical importance.
Hospitalization does not include the following:

Rehabilitation facilities;

Hospice facilities;

Respite care (eg, caregiver relief);

Skilled nursing facilities;

Nursing homes;

Same-day surgeries (as outpatient/same-day/ambulatory procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:

Admission for treatment of a preexisting condition not associated with the development 
of a new AE or with a worsening of the preexisting condition (eg, for workup of a 
persistent pretreatment laboratory abnormality);

Social admission (eg, subject has no place to sleep);

Administrative admission (eg, for yearly physical examination);

Protocol-specified admission during a study (eg, for a procedure required by the study 
protocol);

Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery);

Hospitalization for observation without a medical AE;

Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery, should not 
be reported as SAEs.  However, the medical condition for which the procedure was 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 61
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy should be recorded as treatment of the 
AE.
8.3. Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity of the AE.  For purposes of 
consistency, these intensity grades are defined as follows:
MILD
Does not interfere with subject's usual function.
MODERATE
Interferes to some extent with subject's usual function.
SEVERE
Interferes significantly with subject's usual function.
Note the distinction between the severity and the seriousness of an AE.  A severe event is not 
necessarily an SAE.  For example, a headache may be severe (interferes significantly with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4. Special Situations
8.4.1. Protocol-Specified Serious Adverse Events
There are no protocol-specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety by the investigator as described in previous sections, and will be handled as SAEs in 
the safety database.
8.4.2. Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury, but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury, commonly referred to as drug-induced liver injury 
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal (× ULN) should be monitored more frequently to determine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safety monitoring procedure in this 
study.  However, should an investigator deem it necessary to assess LFTs because a subject 
presents with clinical signs/symptoms, such LFT results should be managed and followed as 
described below.
In the majority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) by several 
days or weeks.  The increase in TBili typically occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/ALT and TBili values will be elevated within the same laboratory

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 62
sample).  In rare instances, by the time TBili elevations are detected, AST/ALT values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy’s law criteria) cases and should always be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underlying conditions.  Subjects who present with the 
following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) 
cases to definitively determine the etiology of the abnormal laboratory values:

Subjects with AST/ALT and TBili baseline values within the normal range who 
subsequently present with AST OR ALT values >3 × ULN AND a TBili value >2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not 
available;

For subjects with baseline AST OR ALT OR TBili values above the ULN, the following 
threshold values are used in the definition mentioned above, as needed, depending on 
which values are above the ULN at baseline:
o
Preexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller).
o
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value by an amount of at least 1 × ULN or if the value reaches >3 × ULN 
(whichever is smaller).
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory tests, detailed history, and physical assessment.
In addition to repeating measurements of AST and ALT and TBili, laboratory tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma-glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase, and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology.  A detailed 
history, including relevant information, such as review of ethanol, acetaminophen (either by 
itself or as a coformulated product in prescription or over-the-counter medications), 
recreational drug, supplement (herbal) use and consumption, family history, sexual history, 
travel history, history of contact with a jaundiced person, surgery, blood transfusion, history 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 63
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary tract) may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study during pregnancy or breastfeeding and 
occupational exposure are reportable to Pfizer Safety within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
Details of all pregnancies in female participants and female partners of male participants will 
be collected after the start of study intervention and until the end of the subject’s 
participation.
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy 
.
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safety within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may or may not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 64
SAE.  Since the information does not pertain to a subject enrolled in the study, the 
information is not recorded on a CRF; however, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors and Lack of Efficacy
Other exposures to the investigational product under study may occur in clinical trial settings, 
such as medication errors and lack of efficacy.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
Medication errors and lack of 
efficacy
All (regardless of whether 
associated with an AE)
Only if associated with an 
SAE
8.4.4.1. Medication Errors
Medication errors may result from the administration or consumption of the investigational 
product by the wrong subject, or at the wrong time, or at the wrong dosage strength.
Medication errors include:

Medication errors involving subject exposure to the investigational product;

Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participating subject;

The administration of expired investigational product;

The administration of an incorrect investigational product;

The administration of an incorrect dosage;

The administration of investigational product that has undergone temperature excursion 
from the specified storage range, unless it is determined by the sponsor that the 
investigational product under question is acceptable for use.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately.
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, any associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 65
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4.4.2. Lack of Efficacy
Lack of efficacy in an approved indication should be reported as an SAE to Pfizer Safety.
8.5. Medical Device Complaint Reporting Requirements
All medical device complaints (prefilled syringes at Vaccination 1), regardless of whether the 
medical device complaint is associated with an AE, will be recorded on the applicable pages 
within the CRF.  This includes potential incidents or malfunctions associated with the use of 
a medical device product.  An incident or malfunction is an event that might have led to 
death or serious deterioration in health, or if it occurred again might lead to death or serious 
deterioration in health.
Pfizer is to be notified of all medical device complaints within 24 hours of the investigator’s 
awareness of the event. 
Medical device complaints should be forwarded to Pharmaceutical Sciences.
9. DATA ANALYSIS/STATISTICAL METHODS
Methodology for summary and statistical analyses of the data collected in this study is 
outlined here and further detailed in a statistical analysis plan (SAP), which will be 
maintained by the sponsor.  The SAP may modify what is outlined in the protocol where 
appropriate; however, any major modifications of the primary endpoint definitions or their 
analyses will also be reflected in a protocol amendment.
9.1. Sample Size Determination and Hypothesis Testing
9.1.1. Cohort 1 (Subjects 60 Years of Age and Older)
Hypothesis testing will be used to assess noninferiority between the 20vPnC/saline and 
13vPnC/PPSV23 vaccine groups in Cohort 1 (subjects 60 years of age and older) for the 
primary endpoint for each of the 20 serotypes.  The null hypothesis for each serotype-specific 
OPA titer is
H0: ln(μA) – ln(μB) ≤ ln(0.5)
where ln(0.5) corresponds to a 2-fold margin for noninferiority and 

ln(μA) is the natural log of the geometric mean OPA titer 1 month after 20vPnC 
administration for the 20vPnC/saline group;

ln(μB) is the natural log of the geometric mean OPA titer 1 month after 13vPnC 
administration for the 13vPnC/PPSV23 group when the endpoint is the geometric 
mean OPA titer from 1 of the shared 13 serotypes in 13vPnC or

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 66
•
ln(μB) is the natural log of the geometric mean OPA titer 1 month after PPSV23 
administration for the 13vPnC/PPSV23 group when the endpoint is the geometric 
mean OPA titer from 1 of the 7 additional serotypes.
Noninferiority for serotype-specific OPA geometric mean titers (GMTs) will be formally 
evaluated by a 
 confidence interval (CI) for the ratio of serotype-specific OPA 
GMTs (20vPnC/saline group over 13vPnC/PPSV23 group) with results from 1 month after 
vaccination with 20vPnC (Visit 2) and 1 month after 13vPnC (Visit 2) for the 13 matched 
serotypes, and 1 month after PPSV23 (Visit 3) for the 7 additional serotypes from all subjects 
at the primary analysis. Noninferiority for a serotype will be declared if the lower bound of 
the 
CI for the geometric mean ratio (GMR) of GMTA/GMTB is greater than 
0.5 (2-fold criterion). 
 
Sample size and power for Cohort 1 are based on simulations with assumptions supported by 
the OPA results from an ongoing Phase 2 study of 20vPnC (B7471002) and an efficacy study 
of 13vPnC in subjects 65 years of age and older (CAPiTA).  Assuming the true GMRs and 
variance-covariance matrices for the 20 serotype-specific OPA titers from subjects 
60 through 64 years of age (~ two-thirds of the evaluable population in Cohort 1) are the 
same as that obtained from B7471002, and with the same assumed OPA GMRs and 
adjustments for variance assumptions 
 from subjects ≥65 years of age
(~ one-third of the evaluable population in Cohort 1), the estimated probabilities to 
demonstrate noninferiority for at least 18 out of 20, at least 19 out of 20, and for all 
20 serotypes are approximately 99%, 96%, and 72%, respectively, assuming 1350 evaluable 
subjects in each group.
CCI
CCI
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 67
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 68
9.1.2. Cohort 2 (Subjects 50 Through 59 Years of Age) and Cohort 3 (Subjects 18
Through 49 Years of Age) Compared to Subjects 60 Through 64 Years of Age From 
Cohort 1
Hypothesis testing will be used to assess noninferiority between each of the 2 younger 
cohorts and the 60 through 64 years of age from Cohort 1 for each of the 20 serotype-specific 
OPA titers.  Testing will be performed only for subjects receiving 20vPnC. The null 
hypothesis for each serotype-specific OPA titer is
H0: ln(μC) – ln(μA) ≤ ln(0.5)
where ln(0.5) corresponds to a 2-fold margin for noninferiority and
•
ln(μC) is the natural log of the geometric mean OPA titer 1 month after 20vPnC 
administration for the younger group, subjects 50 through 59 years of age
(Cohort 2) or subjects 18 through 49 years of age (Cohort 3);
•
ln(μA) is the natural log of the geometric mean OPA titer 1 month after 20vPnC 
administration for subjects 60 through 64 years of age from Cohort 1.
Noninferiority for serotype-specific OPA GMTs will be evaluated by a 2-sided 95% CI for 
the ratio of serotype-specific OPA GMTs (younger/older) with results 1 month after 
vaccination (Visit 2) from all subjects receiving 20vPnC.  Noninferiority will be declared for 
a serotype if the lower bound of the 2-sided 95% CI for the GMR of GMTC/GMTA is greater
than 0.5 (2-fold criterion).
With the planned sample sizes in Cohorts 2 and 3 and assuming that approximately 
900 evaluable subjects enrolled in Cohort 1 will be 60 through 64 years of age, the study has 
greater than 90% power to demonstrate noninferiority in serotype-specific OPA GMRs for all 
20  serotypes  
 
 
9.2. Analysis Populations
Safety and immunogenicity results from each cohort will be analyzed separately within each 
cohort with the exception of the immunogenicity bridging analysis that compares the 20vPnC 
results from each of Cohort 2 and Cohort 3 to subjects 60 through 64 years of age from 
Cohort 1 as detailed in Section 9.3.2.
9.2.1. Safety Population
The safety population will include all subjects who receive at least 1 dose of 20vPnC, 
13vPnC, PPSV23, or saline and have reported safety data.  Subjects will be included in the 
vaccine group corresponding to the vaccine actually received.  The safety population will be 
the only analysis population for safety endpoints.
C
C
I
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 69
9.2.2. Immunogenicity Population for Cohort 1
Two evaluable immunogenicity populations are defined for the analyses of the 
immunogenicity results: the evaluable 13-matched immunogenicity population and the 
evaluable 7-additional immunogenicity population. The evaluable 13-matched 
immunogenicity population will be the primary analysis population for immunogenicity
results of the 13 matched serotypes in Cohort 1.  This population will generally include any 
subject who:
1. receives the first vaccine as randomized,
2. is enrolled in the appropriate cohort based on age on the day of first vaccination 
(ie, 60 years of age and older in Cohort 1),
3. has Visit 2 blood collection within an appropriate window for Visit 2,
4. has at least 1 valid and determinate OPA titer for any of the 13 matched serotypes at 
Visit 2, 
5. does not receive any prohibited vaccinations after Vaccination 1 and before Visit 2, and
6. has no other major protocol deviations as determined by the clinician.
The evaluable 7-additional immunogenicity population will be the primary analysis 
population for immunogenicity examination of the 7 additional serotypes in Cohort 1.  This 
population will generally include any subject who:
1. receives the vaccine sequence (20vPnC/saline or 13vPnC/PPSV23) as randomized,
2. is enrolled in the appropriate cohort based on age on the day of first vaccination 
(ie, 60 years of age and older in Cohort 1),
3. has either Visit 2 blood collection for the 20vPnC/saline group or Visit 3 blood collection 
for the 13vPnC/PPSV23 group within appropriate windows for Visit 2 or 3, respectively,
4. has at least 1 valid and determinate OPA titer for any of the 7 additional serotypes at 
either Visit 2 for the 20vPnC/saline group or Visit 3 for the 13vPnC/PPSV23 group,
5. does not receive any prohibited vaccinations after Vaccination 1 and before Visit 2 from 
the 20vPnC/saline group, or after Vaccination 1 and before Visit 3 from the 
13vPnC/PPSV23 group, and
6. has no other major protocol deviations as determined by the clinician.
Subjects will be included in the vaccine group as randomized in the analyses of evaluable 
subjects.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 70
9.2.3. Immunogenicity Population for Comparison of Cohorts 2 and 3 to Cohort 1
A third evaluable immunogenicity population, evaluable-20 immunogenicity population, is 
defined for the comparisons of subjects 60 through 64 years of age from Cohort 1 to the other 
2 younger age cohorts (Cohort 2: 50 through 59 years of age; and Cohort 3: 18 through 
49 years of age), limited to subjects receiving 20vPnC.  This population will generally 
include any subject who:
1. receives the vaccine (Vaccination 1 for Cohort 1) as randomized,
2. is enrolled in the appropriate cohort based on age on the day of first vaccination 
(ie, 60 through 64 years of age for Cohort 1, 50 through 59 years of age for Cohort 2, and 
18 through 49 years of age for Cohort 3),
3. has Visit 2 blood collection within an appropriate window for Visit 2,
4. has at least 1 valid and determinate OPA titer for any of the 20 serotypes for Visit 2,
5. does not receive any prohibited vaccinations after the vaccination at Visit 1 and before 
Visit 2, and
6. has no other major protocol deviations as determined by the clinician.
The evaluable-20 immunogenicity population will also be the primary analysis population for 
immunogenicity results from Cohort 2 and Cohort 3. Subjects will be included in the vaccine 
group as randomized in the analysis based on the evaluable-20 immunogenicity population.
 
 
 
 
9.2.5. Analysis of Demographic and Clinical Characteristics
The demographic characteristics, which will include sex, race, ethnicity, age at the time of 
randomization, and smoking history, will be summarized using descriptive statistics.  
Demographic characteristics will be summarized for each vaccine group separately for each 
cohort.
9.3. Immunogenicity Analyses
All statistical analyses for serotype-specific OPA titers will be done on the natural log scale, 
and the results will be reported on the original scale after back transformation.
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 71
Missing assay results will not be replaced or imputed. OPA LLOQ values and conventions to 
handle OPA titers below the LLOQ or below the limit of quantitation will be described in the 
SAP.
 
 
 
 
 
9.3.1. Immunogenicity Analysis Comparing 20vPnC/Saline to 13vPnC/PPSV23 in 
Cohort 1
Analyses of OPA GMTs and GMRs
Serotype-specific OPA GMTs will be calculated based on sera collected before study 
vaccination and 1 month after each vaccination.  Geometric means and their 2-sided CIs will 
be derived by calculating means and CIs on the natural log scale, then exponentiating the 
results.  CIs will be based on the t-distribution.
For each of the 20 primary endpoints corresponding to the serotype-specific OPA titers, the 
GMRs of the 20vPnC/saline GMT to the 13vPnC/PPSV23 GMT will be provided. GMRs 
and their 2-sided CIs will be derived by calculating differences in means and CIs on the 
natural log scale, then exponentiating the results.
The difference in means, on the natural log scale, will be 20vPnC/saline minus 
13vPnC/PPSV23 for the 13 matched serotypes at Visit 2 or 20vPnC/saline at Visit 2 minus 
13vPnC/PPSV23 at Visit 3 for the 7 additional serotypes.  CIs will be based on the 
t-distribution. 
 
Other Immunogenicity Analyses Based on OPA Titer
OPA GMFRs will be summarized for each vaccine serotype from Visit 1 to Visit 2 for the 
13 matching serotypes.  For the 7 additional serotypes, the GMFR will be summarized from 
Visit 1 to Visit 2 for the 20vPnC/saline vaccine group and from Visit 1 to Visit 3 for the 
13vPnC/PPSV23 vaccine group.  GMFRs will be limited to subjects with nonmissing values 
both before any vaccination and after the indicated vaccination.  Two-sided CIs will be 
included.
CCI
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 72
The proportion of subjects with OPA titers ≥LLOQ will be provided for time points and
serotypes noted in the paragraph above.  The associated 2-sided CIs will be obtained using 
the Clopper-Pearson method.
The proportion of subjects with a 4-fold rise in serotype-specific OPA titer from Visit 1 to 
Visit 2 (20vPnC/saline group for all 20 serotypes, and 13vPnC/PPSV23 group for the 
13 matching serotypes) or Visit 3 (13vPnC/PPSV23 group for the 7 additional serotypes) will 
be provided. The assessment of a 4-fold rise will be based on the increase from Visit 1 to 
Visit 2 for the 20 serotypes in subjects receiving 20vPnC as well as for the 13 matched 
serotypes in subjects receiving 13vPnC, and on the increase from Visit 1 to Visit 3 for the 
7 additional serotypes in subjects receiving 13vPnC/PPSV23.  The associated 2-sided CIs 
will be obtained using the Clopper-Pearson method.
9.3.2. Immunogenicity Analysis Comparing Younger Cohorts (Subjects 50 Through 59
Years of Age and Subjects 18 Through 49 Years of Age) to Subjects 60 Through 64
Years of Age From Cohort 1, Limited to Subjects Receiving 20vPnC (Bridging 
Analyses)
The analyses of all 20 serotypes will be based on subjects who received 20vPnC.
Serotype-specific OPA GMTs will be calculated from sera collected before study vaccination 
and 1 month after vaccination (Visit 2).  Geometric means and their 2-sided 95% CIs will be 
derived by calculating means and CIs on the natural log scale, then exponentiating the 
results.  CIs will be based on the t-distribution.
The GMRs of the younger-cohort GMT to the older-cohort GMT will be provided for OPA 
responses. “Younger” refers to either Cohort 3 (subjects 18 through 49 years of age) or 
Cohort 2 (subjects 50 through 59 years of age).  “Older” refers to subjects 60 through 
64 years of age from Cohort 1.  The responses from the 20 serotypes will be obtained from 
Visit 2.  Two-sided 95% CIs will be included.
GMRs and their 2-sided 95% CIs will be derived by calculating differences in means and CIs 
on the natural log scale, then exponentiating the results.  The difference in means, on the 
natural log scale, will be the younger cohort (Cohort 2 or Cohort 3) minus the older cohort 
(Cohort 1).  CIs will be based on the t-distribution.  The OPA results from the younger cohort 
will be declared noninferior to those from subjects 60 through 64 years of age from Cohort 1 
for a specific serotype if the lower 2-sided 95% confidence limit for the serotype-specific 
OPA GMR exceeds 0.5.
9.3.3. Other Immunogenicity Analyses for Cohorts 2 and 3 Based on OPA Titer of 
20vPnC
OPA GMFRs will be summarized for each vaccine serotype in the 20vPnC group in Cohorts 
2 and Cohort 3 from Visit 1 to Visit 2.  GMFRs will be limited to subjects with nonmissing 
values both before and after vaccination.
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 73
The proportion of subjects with OPA titers ≥LLOQ will be provided for each time point and 
serotype.  The associated 95% CIs will be obtained using the Clopper-Pearson method.
The proportion of subjects with a 4-fold rise in serotype-specific OPA titer from before to 
1 month after vaccination will also be provided for each serotype in the 20vPnC groups in 
Cohort 2 and Cohort 3.  The associated 95% CIs will be obtained using the Clopper-Pearson 
method.
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 74
9.3.7. Other Immunogenicity Analyses
Descriptive statistics of serotype-specific OPA results may be provided for subpopulations 
(ie, different age groups).  Descriptive statistics may include GMTs, GMFRs, and 
percentages with OPA titers ≥LLOQ.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 75
9.4. Safety Analysis
9.4.1. Adverse Events
AEs will be categorized according to the Medical Dictionary for Regulatory Activities 
(MedDRA) and will be summarized by vaccine group within cohort.  A 3-tier approach will 
be used to summarize AEs. Under this approach AEs are classified into 1 of 3 tiers:
•
Tier 1 events: These are prespecified events of clinical importance and are identified in a 
list in the product’s safety review plan. p-Values and 95% CIs for between-group 
comparisons (risk differences) will be provided for Tier 1 events. At this development 
stage for 20vPnC, no Tier 1 events have been identified.
•
Tier 2 events: These are events that are not Tier 1, but are considered “relatively 
common.”  A MedDRA preferred term is defined as a Tier 2 event if there is an incidence 
of at least 4 events in any AE in any vaccine group and any cohort. 95% CIs for 
between-group comparisons (risk differences) will be provided for Tier 2 events.
•
Tier 3 events: These are events that are neither Tier 1 nor Tier 2 events. Counts and 
percentages for each vaccine group will be provided for Tier 3 events.
The Miettinen and Nurminen method will be used to derive a 95% CI for the risk difference 
between vaccine groups.74
Descriptive summary statistics will be provided for SAEs and NDCMCs for each vaccine 
group and each cohort.
9.4.2. Reactogenicity
Reactogenicity results will be analyzed separately for each cohort. Descriptive statistics will 
be provided for each reactogenicity endpoint for each vaccine group separately within each 
cohort.  In each group/cohort, local reactions from Day 1 through Day 10 and systemic 
events from Day 1 through Day 7 after the first vaccination will be presented by severity and 
cumulatively across severity levels.  Descriptive summary statistics will include proportions 
of subjects with the indicated endpoint and the associated Clopper-Pearson 95% CIs.
 
 
 
 
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 76
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may review source documents to 
confirm that the data recorded on CRFs are accurate.  The investigator and institution will 
allow Pfizer monitors/auditors or its agents and appropriate regulatory authorities direct 
access to source documents to perform this verification.  This verification may also occur 
after study completion.
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 77
During study conduct and/or after study completion, the investigator site may be subject to 
review by the IRB/EC, and/or to quality assurance audits performed by Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by appropriate regulatory 
authorities.
The investigator(s) will notify Pfizer or its agents immediately of any regulatory inspection 
notification in relation to the study.  Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve any discrepancies that are identified between the study 
data and the subject's medical records.  The investigator will promptly provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity to review 
and comment on responses to any such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11. DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study.
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole property of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory 
authorities, without written permission from Pfizer.  The investigator shall ensure that the 
CRFs are securely stored at the study site in encrypted electronic form and will be password 
protected to prevent access by unauthorized third parties.
The investigator has ultimate responsibility for the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, complete, 
consistent, legible, timely (contemporaneous), enduring, and available when required.  The 
CRFs must be signed by the investigator or by an authorized staff member to attest that the 
data contained on the CRFs are true.  Any corrections to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry.
In most cases, the source documents are the hospital or the physician subject chart.  In these 
cases, data collected on the CRFs must match the data in those charts.
In some cases, the CRF may also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that clearly identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 78
11.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
ICDs, copies of all CRFs, safety reporting forms, source documents, and detailed records of 
treatment disposition, and adequate documentation of relevant correspondence (eg, letters, 
meeting minutes, and telephone call reports).  The records should be retained by the 
investigator according to the ICH guidelines, according to local regulations, or as specified in 
the clinical study agreement (CSA), whichever is longer.  The investigator must ensure that 
the records continue to be stored securely for so long as they are retained.
If the investigator becomes unable for any reason to continue to retain study records for the 
required period (eg, retirement, relocation), Pfizer should be prospectively notified.  The 
study records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or an independent third party arranged by Pfizer.
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of any records, 
even if retention requirements have been met.
12. ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, ICDs, and other relevant documents, eg, recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator file.  Copies of IRB/EC approvals should be forwarded to Pfizer.
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify the IRB/EC and Pfizer in writing immediately after 
the implementation.
12.2. Ethical Conduct of the Study
The study will be conducted in accordance with the protocol, legal and regulatory 
requirements, and the general principles set forth in the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences [CIOMS] 2002), ICH Guideline for Good Clinical Practice, and the 
Declaration of Helsinki.
12.3. Subject Information and Consent
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of subject personal data.  Such 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 79
measures will include omitting subject names or other directly identifiable data in any 
reports, publications, or other disclosures, except where required by applicable laws.
The personal data will be stored at the study site in encrypted electronic form and will be 
password protected to ensure that only authorized study staff have access.  The study site will 
implement appropriate technical and organizational measures to ensure that the personal data 
can be recovered in the event of disaster.  In the event of a potential personal data breach, the 
study site shall be responsible for determining whether a personal data breach has in fact 
occurred and, if so, providing breach notifications as required by law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, when study data are compiled for transfer to Pfizer and other authorized 
parties, subject names will be removed and will be replaced by a single, specific, numerical 
code based on a numbering system defined by Pfizer.  All other identifiable data transferred 
to Pfizer or other authorized parties will be identified by this single, subject-specific code.  
The investigator site will maintain a confidential list of subjects who participated in the 
study, linking each subject’s numerical code to his or her actual identity.  In case of data 
transfer, Pfizer will maintain high standards of confidentiality and protection of subjects’ 
personal data consistent with the CSA and applicable privacy laws.
The ICDs and any subject recruitment materials must be in compliance with ICH GCP, local 
regulatory requirements, and legal requirements, including applicable privacy laws.
The ICDs used during the informed consent process and any subject recruitment materials 
must be reviewed and approved by Pfizer, approved by the IRB/EC before use, and available 
for inspection.
The investigator must ensure that each study subject is fully informed about the nature and 
objectives of the study, the sharing of data relating to the study, and possible risks associated 
with participation, including the risks associated with the processing of the subject’s personal 
data.  The investigator further must ensure that each study subject is fully informed about his 
or her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The investigator, or a person designated by the investigator, will obtain written informed 
consent from each subject before any study-specific activity is performed.  The investigator 
will retain the original of each subject's signed consent document.
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 80
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study subjects against any immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13. DEFINITION OF END OF TRIAL
13.1. End of Trial in All Participating Countries 
End of trial in all participating countries is defined as last subject last visit (LSLV). After 
this time, sites will be closed out, the IRB/EC will be informed, and no further CIOMS 
reports will be sent.
14. SPONSOR DISCONTINUATION CRITERIA
Premature termination of this study may occur because of a regulatory authority decision, 
change in opinion of the IRB/EC, or investigational product safety problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
20vPnC at any time.
If a study is prematurely terminated, Pfizer will promptly notify the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy 
(if applicable) within 30 days.  As directed by Pfizer, all study materials must be collected 
and all CRFs completed to the greatest extent possible.
15. PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer-sponsored 
interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a 
Pfizer product, regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary outcome, whether the clinical study 
concluded according to the prespecified protocol or was terminated.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 81
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer-sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Synopses (clinical study report synopses in which any data 
that could be used to identify individual patients has been removed) on www.pfizer.com for 
Pfizer-sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by the 
PI of the results of the study based on information collected or generated by the PI, whether 
or not the results are favorable to the Pfizer product.  However, to ensure against inadvertent 
disclosure of confidential information or unprotected inventions, the investigator will provide 
Pfizer an opportunity to review any proposed publication or other type of disclosure of the 
results of the study (collectively, “publication”) before it is submitted or otherwise disclosed.
The investigator will provide any publication to Pfizer at least 30 days before it is submitted 
for publication or otherwise disclosed.  If any patent action is required to protect intellectual 
property rights, the investigator agrees to delay the disclosure for a period not to exceed an 
additional 60 days.
The investigator will, on request, remove any previously undisclosed confidential 
information before disclosure, except for any study- or Pfizer product-related information 
necessary to the appropriate scientific presentation or understanding of the study results.
If the study is part of a multicenter study, the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that any subsequent publications 
by the PI will reference that primary publication.  However, if a joint manuscript has not 
been submitted for publication within 12 months of completion or termination of the study at 
all participating sites, the investigator is free to publish separately, subject to the other 
requirements of this section.
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including Section II - “Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by the International Committee of Medical Journal Editors.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 82
Publication of study results is also provided for in the CSA between Pfizer and the 
institution.  In this section entitled Publications by Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is any conflict between the CSA and any attachments to it, the terms of the CSA 
control.  If there is any conflict between this protocol and the CSA, this protocol will control 
as to any issue regarding treatment of study subjects, and the CSA will control as to all other 
issues.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 83
16. REFERENCES
1.
Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL; for the AGEDD 
Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal 
pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. 
PLoS One. 2013;8(4):e60273.
2.
O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus 
pneumoniae in children younger than 5 years: global estimates. Lancet. 
2009;374(9693):893-902.
3.
Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal 
disease in the United States. Vaccine. 2011;29(18):3398-3412.
4.
Iyer AS, Ohtola JA, Westerink MAJ. Age-related immune response to pneumococcal 
polysaccharide vaccination: lessons for the clinic. Expert Rev Vaccines. 2015;14(1):85-97.
5.
Jain S, Williams DJ, Arnold SR, et al; for the CDC EPIC Study Team. 
Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl 
J Med. 2015;372(9):835-845.
6.
Jain S, Self WH, Wunderink RG, et al; for the CDC EPIC Study Team.  
Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl 
J Med. 2015;373(5):415-427.
7.
Earle K, Williams S. Burden of pneumococcal disease in adults aged 65 years and 
older: an Australian perspective. Pneumonia. 2016;8:9.
8.
Troeger C, Forouzanfar M, Rao PC, et al; GBD 2015 LRI Collaborators. Estimates of 
the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory 
tract infections in 195 countries: a systematic analysis for the Global Burden of Disease 
Study 2015. Lancet Infect Dis. 2017;17(11):1133-1161.
9.
Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program 
Network, Streptococcus pneumoniae, 2016. https://www.cdc.gov/abcs/reports-
findings/survreports/spneu16.pdf. Accessed 23 May 2018.
10.
Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, 
present, and future. Clin Microbiol Rev. 2015;28(3):871-899.
11.
Hausdorff WP, Hanage WP. Interim results of an ecological experiment-conjugate 
vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother.
2016;12(2):358-374.
12.
Alonso DeVelasco E, Verheul AFM, Verhoef J, Snippe H. Streptococcus pneumoniae: 
virulence factors, pathogenesis, and vaccines. Microbiol Rev. 1995;59(4):591-603.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 84
13.
Prevention of pneumococcal disease: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
14.
Austrian R. A brief history of pneumococcal vaccines. Drugs Aging.
1999;15(suppl 1):1-10.  
15.
Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent 
pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453-1460.
16.
Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide 
antigens. J Infect Dis. 1992;165 Suppl 1:S49-S52.
17.
Borrow R, Health PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in 
children: what is the evidence? Curr Opin Infect Dis. 2012;25(3):292-303.
18.
Jackson LA, Neuzil KM, Yu O, et al; for the Vaccine Safety Datalink. Effectiveness of 
pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 
2003;348(18):1747-1755.
19.
Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. 
Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease 
and hospital-treated pneumonia among people aged 65 years: a retrospective case-control 
study. Clin Infect Dis. 2015;60(10):1472-1480.
20.
Wright PF, Sell SH, Vaughn WK, Andrews C, McConnell KB, Schiffman G. Clinical 
studies of pneumococcal vaccines in infants. II. Efficacy and effect on nasopharyngeal 
carriage. Rev Infect Dis. 1981;3 Suppl:S108-S112.
21.
Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent 
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in 
pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364-2374.
22.
Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 
13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide 
vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination 
in adults 50 years and older. Vaccine. 2013;31(35):3594-3602.
23.
Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent 
pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously 
treated for pneumonia. Vaccine. 2003;22(1):96-103.
24.
Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after 
vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011; 
10(3):307-322.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 85
25.
Updated recommendations for prevention of invasive pneumococcal disease among 
adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb 
Mortal Wkly Rep. 2010;59(34):1102-1106.
26.
Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention. 
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal 
polysaccharide vaccine among adults aged 65 years: recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 
2014;63(37):822-825.
27.
Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. 
Pneumococcal vaccination: what have we learnt so far and what can we expect in the 
future? Eur J Clin Microbiol Infect Dis. 2015;34(1):19-31.
28.
Robinson KA, Baughman W, Rothrock G, et al; for the Active Bacterial Core 
Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive 
Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for 
prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729-1735.
29.
Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups 
cause the most invasive disease: implications for conjugate vaccine formulation and use, 
part I. Clin Infect Dis. 2000;30(1):100-121.
30.
Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific 
pneumococcal serogroups to different disease manifestations: implications for conjugate 
vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122-140.
31.
Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and 
children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal 
polysaccharide vaccine - recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR Recomm Rep. 2010.59(RR-11):1-18.
32.
Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes 
causing invasive pneumococcal disease among children under five: the Pneumococcal 
Global Serotype Project. PLoS Med. 2010;7(10):1-13.
33.
Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal 
serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. 
Emerg Infect Dis. 2013;19(7):1074-1083.
34.
Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal 
conjugate vaccine in children younger than five years of age for prevention of pneumonia. 
Pediatr Infect Dis J. 2002;21(9):810-815.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 86
35.
Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal 
conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: 
updated analysis using World Health Organization standardized interpretation of chest 
radiographs. Pediatr Infect Dis J. 2006;25(9):779-781.
36.
Cutts FT, Zaman SM, Enwere G, et al; Gambian Pneumococcal Vaccine Trial Group. 
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive 
pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. 
Lancet. 2005;365(9465):1139-1146.
37.
Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; for the 
Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children 
with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348.
38.
Whitney CG, Farley MM, Hadler J, et al; for the Active Bacterial Core Surveillance of 
the Emerging Infections Program Network. Decline in invasive pneumococcal disease after 
the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 
2003;348(18):1737-1746.
39.
Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging 
Infections Program Network. Sustained reductions in invasive pneumococcal disease in the 
era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
40.
Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent 
pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev 
Vaccines. 2010;9(3):229-236.
41.
Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine 
against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125.
42.
Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal 
conjugate vaccine (PCV13) and recommendations for use among children -- Advisory 
Committee on Immunization Practices (ACIP), 2010.  MMWR Morb Mortal Wkly Rep.
2010;59(9):258-261.
43.
Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal 
conjugate vaccine for adults aged 50 years and older.  MMWR Morb Mortal Wkly Rep. 
2012;61(21):394-395.
44.
Prevenar 13 Summary of Product Characteristics. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/001104/WC500057247.pdf. Accessed 12 Sep 2016.
45.
European Medicines Agency. Prevenar 13 Assessment Report. 22 January 2015.  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-
_Variation/human/001104/WC500186805.pdf. Accessed 12 Sep 2016.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 87
46.
World Health Organization. WHO Prequalified Vaccines. Pneumococcal (conjugate). 
Prevenar 13. https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=221. 
Effective 20 Aug 2010. Accessed 19 Jul 2018.
47.
World Health Organization. WHO Prequalified Vaccines. Pneumococcal (conjugate). 
Prevenar 13 Multidose Vial. 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=317. 
Effective 14 Jul 2016. Accessed 12 Sep 2016.
48.
Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal 
conjugate vaccination in invasive pneumococcal disease incidence and mortality [erratum 
appears in Clin Infect Dis. 2014;59(12):1812]. Clin Infect Dis. 2014;59(8):1066-1073.
49.
Steens A, Bergsaker MA, Aaberge IS, Ronnig K, Vestrheim DF. Prompt effect of 
replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the 
epidemiology of invasive pneumococcal disease in Norway. 
Vaccine. 2013;31(52):6232-6238.
50.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new 
serotypes in the 13-valent pneumococcal conjugate vaccine. 
Vaccine. 2011;29(49):9127-9131.
51.
Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal 
conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged 50 years with 
community-acquired pneumonia. J Infect Dis. 2013;208(11):1813-1820.
52.
Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 
vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947.
53.
Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal 
conjugate vaccine in children on invasive pneumococcal disease in children and adults in 
the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis.
2015;15(3):301-309.
54.
Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes 
causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective 
national observational cohort study. Lancet Infect Dis. 2018;18(4):441-451.
55.
van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of infant 
pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal 
disease among children and adults in Germany. PLoS One. 2015;10(7):1-17.
56.
Cohen R, Biscardi S, Levy C. The multifaceted impact of pneumococcal conjugate 
vaccine implementation in children in France between 2001 to 2014. Hum Vaccines 
Immunother. 2016;12(2):277-284.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 88
57.
Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent 
pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children 
with acute otitis media. Pediatr Infect Dis J. 2012;31(3):297-301.
58.
Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate 
vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional 
study. PLoS Med. 2011;8(4):e1001017.
59.
Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive 
pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal 
conjugate vaccine. Med J Aust. 2011;194(3):116-120.
60.
Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant 
pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro 
Surveill. 2008;13(35):18962.
61.
Munoz-Almagro C, Ciruela P, Esteva C, et al; for the Catalan Study Group of Invasive 
Pneumococcal Disease. Serotypes and clones causing invasive pneumococcal disease 
before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 2011;63(2):151-162.
62.
Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children 
provokes new patterns of serotypes causing invasive pneumococcal disease in adults and 
children. Am J Med Sci. 2013;345(2):112-120.
63.
Adam HJ, Karlowsky JA, Nichol KA, et al. Baseline epidemiology of Streptococcus 
pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal 
vaccine. Microb Drug Resist. 2012;18(2):176-182.
64.
Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr; U.S. Pediatric 
Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 
and 33: an increasing cause of pneumococcal infections in children in the United States 
after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis 
J. 2006;25(4):301-305.
65.
Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality 
following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 
2009;6(5):e1000081.
66.
Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic 
resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J.
2012;31(3):249-254.
67.
Cohen R, Varon E, Doit C, et al. A 13-year survey of pneumococcal nasopharyngeal 
carriage in children with acute otitis media following PCV7 and PCV13 implementation. 
Vaccine. 2015;33(39):5118-5126.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 89
68.
Yildirim I, Little BA, Finkelstein J. et al; The Massachusetts Dept. of Public Health.
Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals 
shift in prevalent carriage serotypes in Massachusetts’ children to relatively low 
invasiveness. Vaccine. 2017;35(32):4002-4009.
69.
Ciu YA, Patel H, O’Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: a
snapshot of recent data in pediatric and adult populations around the world. Hum Vaccines 
Immunother. 2017;13(6):1229-1241.
70.
Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-
generation pneumococcal capsular polysaccharide vaccine with emphasis on the 
cross-reactive types within groups. J Infect Dis. 1983;148(6):1136-1159.
71.
International Committee on Harmonisation. Statistical Principles for Clinical Trials. 
ICH Harmonised Tripartite Guideline E9, February 1998.
72.
Food and Drug Administration, Center for Biologics Evaluation and Research. Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials. Guidance for Industry, September 2007.
73.
Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate 
vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with 
immunocompromising conditions: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40): 816-819.
74.
Miettinen O, Nurminen M. Comparative analysis of 2 rates. Stat Med. 1985; 
4(2):213-226.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 90
Appendix 1. Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation
Term
7vPnC
7-valent pneumococcal conjugate vaccine
13vPnC
13-valent pneumococcal conjugate vaccine
20vPnC
20-valent pneumococcal conjugate vaccine
ACIP
Advisory Committee on Immunization Practices
AE
adverse event
ALT
alanine aminotransferase
AOM
acute otitis media
AST
aspartate aminotransferase
CAP
community-acquired pneumonia
CAPiTA
Community-Acquired Pneumonia Immunization Trial in Adults
CBER
Center for Biologics Evaluation and Research
CDC
Centers for Disease Control and Prevention
CI
confidence interval
CIOMS
Council for International Organizations of Medical Sciences
CK
creatine kinase
COPD
chronic obstructive pulmonary disease
CRF
case report form
CRM197
cross-reactive material 197
CSA
clinical study agreement
CT
clinical trial
DILI
drug-induced liver injury
DU
dispensable unit
EC
ethics committee
e-diary
electronic diary
EDP
exposure during pregnancy
EU
European Union
EudraCT
European Clinical Trials Database
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
GGT
gamma-glutamyl transferase
GMFR
geometric mean fold rise
GMR
geometric mean ratio
GMT
geometric mean titer
HIV
human immunodeficiency virus
HRT
hormone replacement therapy
IB
investigator’s brochure
ICD
informed consent document
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 91
Abbreviation
Term
ICH
International Council for Harmonisation
ID
identification
IND
investigational new drug application
INR
international normalized ratio
IP manual
Investigational Product Manual
IPD
invasive pneumococcal disease
IRB
institutional review board
IRT
interactive response technology
IUD
intrauterine device
IUS
intrauterine hormone-releasing system
IWR
interactive Web-based response
LFT
liver function test
LLOQ
lower limit of quantitation
LRI
lower respiratory tract infection
LSLV
last subject last visit 
MedDRA
Medical Dictionary for Regulatory Activities
N/A
not applicable
NDCMC
newly diagnosed chronic medical condition
OPA
opsonophagocytic activity
PCD
primary completion date
PI
principal investigator
PPSV23
23-valent pneumococcal polysaccharide vaccine
PT
prothrombin time
SAE
serious adverse event
SAP
statistical analysis plan
SoA
Schedule of Activities
SRM
study reference manual
SRSD
single reference safety document
TBili
total bilirubin
ULN
upper limit of normal
US
United States
USPI
US package insert
VT
vaccine-type
WHO
World Health Organization
WOCBP
woman of childbearing potential
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 92
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 93
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 94
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 95
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471007
Final Protocol Amendment 2, 11 February 2019
PFIZER CONFIDENTIAL
Page 96
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH
		 
       
 	
'RFXPHQW 7LWOH
		 
       
 	
6LJQHG %\
'DWH*07
6LJQLQJ &DSDFLW\
!
!	 "#"#

 $
!
!	 #(#	

 $
PPD
PPD